KATHERINE PREGEL

Healthcare issues related to clinical laboratories; H.R. 5269/S. 2761,the Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act, provisions relating to reform of Medicare reimbursement for clinical laboratory services under Section 216 of the Protecting Access to Medicare Act, Pub. L. 113-93; H.R. 5582/S. 2355, the Patients Deserve Price Tags Act, and H.R. 9393, the Lower Costs, More Transparency Act, provisions relating to lab test price transparency; H.R. 8500, the Timely Access to Coverage Decisions Act, provisions relating to establishment of standards for Medicare local coverage decisions; H.R. 8890, the Enhancing Clinical Laboratory Innovation and Access (Enhancing CLIA) Act, provisions relating to oversight of laboratory-developed tests; H.R. 9061, the Preeclampsia Risk Evaluation and Evidence-based Management through Personalized Testing (PREEMPT) Act, provisions relating to Medicaid coverage of preeclampsia screening tests; H.R. 8413, the Securing and Establishing Consumer Uniform Rights and Enforcement over Data (SECURE Data) Act, provisions relating to privacy of health care data; A draft of the AI Workforce Assessment and Research (AWARE) Act, provisions relating to disclosure of information on the use and impact of artificial intelligence in employment matters; A draft of the Great American AI Act, provisions relating to regulation of artificial intelligence; Federal policy relating to oversight of laboratory benefit managers; Federal policy relating to access to mandatory code sets for administrative transactions; and Federal policy relating to supply chain issues affecting pre-clinical biomedical research for drug development.

Healthcare issues related to clinical laboratories; H.R. 5269/S. 2761,the Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act, and Section 6226 of H.R. 7148, the Consolidated Appropriations Act, 2026, Pub. L. 119-75, provisions relating to reform of Medicare reimbursement for clinical laboratory services under Section 216 of the Protecting Access to Medicare Act, Pub. L. 113-93; H.R. 6280/S. 3607, the Access to Genetic Counselor Services Act, provisions relating to Medicare coverage of genetic counselor services; H.R. 5582/S. 2355, the Patients Deserve Price Tags Act, provisions relating to lab test price transparency; S. 3315, the Health Care Cybersecurity and Resiliency Act, provisions relating to cybersecurity; Federal policy relating to access to mandatory code sets for administrative transactions; Federal policy relating to oversight of laboratory-developed tests; and Federal policy relating to supply chain issues affecting pre-clinical biomedical research for drug development.

Healthcare issues related to clinical laboratories; H.R. 5269/S. 2761,the Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act, provisions relating to reform of Medicare reimbursement for clinical laboratory services under Section 216 of the Protecting Access to Medicare Act, Pub. L. 113-93; H.R. 5582/S. 2355, the Patients Deserve Price Tags Act, H.R. 9393, the Lower Costs, More Transparency Act, and H.R. 9645, the Health Care Price Certainty for All Americans Act, provisions relating to lab test price transparency; H.R. 9117, the Clear Healthcare Expense Cost Knowledge (CHECK) Act, provisions relating to administrative service provider price transparency and itemized patient billing; S. 3097, the Health Information Privacy Reform Act, provision relating to privacy of health data; H.R. 8500, the Timely Access to Coverage Decisions Act, provisions relating to establishment of standards for Medicare local coverage decisions; H.R. 8890, the Enhancing Clinical Laboratory Innovation and Access (Enhancing CLIA) Act, provisions relating to oversight of laboratory-developed tests; H.R. 6130/S. 3267, the Alzheimers Screening and Prevention (ASAP) Act, provisions relating to Medicare coverage of blood-based dementia screening tests; H.R. 5444, the Medical Laboratory Personnel Shortage Relief Act, provisions relating to amending the Public Health Service Act to address the shortage of medical laboratory personnel; Federal policy relating to prior authorization and oversight of laboratory benefit managers; Federal policy relating to access to mandatory code sets for administrative transactions; and Federal policy relating to supply chain issues affecting pre-clinical biomedical research for drug development.

Healthcare issues related to clinical laboratories; H.R. 5269/S. 2761,the Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act, provisions relating to reform of Medicare reimbursement for clinical laboratory services under Section 216 of the Protecting Access to Medicare Act, Pub. L. 113-93; H.R. 5582/S. 2355, the Patients Deserve Price Tags Act, H.R. 9393, the Lower Costs, More Transparency Act, and H.R. 9645, the Health Care Price Certainty for All Americans Act, provisions relating to lab test price transparency; H.R. 9117, the Clear Healthcare Expense Cost Knowledge (CHECK) Act, provisions relating to administrative service provider price transparency and itemized patient billing; S. 3097, the Health Information Privacy Reform Act, provision relating to privacy of health data; H.R. 8500, the Timely Access to Coverage Decisions Act, provisions relating to establishment of standards for Medicare local coverage decisions; H.R. 8890, the Enhancing Clinical Laboratory Innovation and Access (Enhancing CLIA) Act, provisions relating to oversight of laboratory-developed tests; H.R. 6130/S. 3267, the Alzheimers Screening and Prevention (ASAP) Act, provisions relating to Medicare coverage of blood-based dementia screening tests; H.R. 5444, the Medical Laboratory Personnel Shortage Relief Act, provisions relating to amending the Public Health Service Act to address the shortage of medical laboratory personnel; Federal policy relating to prior authorization and oversight of laboratory benefit managers; Federal policy relating to access to mandatory code sets for administrative transactions; and Federal policy relating to supply chain issues affecting pre-clinical biomedical research for drug development.

Healthcare issues related to clinical laboratories; H.R. 5269/S. 2761,the Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act, and Section 6226 of H.R. 7148, the Consolidated Appropriations Act, 2026, Pub. L. 119-75, provisions relating to reform of Medicare reimbursement for clinical laboratory services under Section 216 of the Protecting Access to Medicare Act, Pub. L. 113-93; H.R. 6280/S. 3607, the Access to Genetic Counselor Services Act, provisions relating to Medicare coverage of genetic counselor services; H.R. 5582/S. 2355, the Patients Deserve Price Tags Act, provisions relating to lab test price transparency; S. 3315, the Health Care Cybersecurity and Resiliency Act, provisions relating to cybersecurity; Federal policy relating to access to mandatory code sets for administrative transactions; Federal policy relating to oversight of laboratory-developed tests; and Federal policy relating to supply chain issues affecting pre-clinical biomedical research for drug development.

Healthcare issues related to clinical laboratories; H.R. 5269/S. 2761,the Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act, and Section 6226 of H.R. 7148, the Consolidated Appropriations Act, 2026, Pub. L. 119-75, provisions relating to reform of Medicare reimbursement for clinical laboratory services under Section 216 of the Protecting Access to Medicare Act, Pub. L. 113-93; H.R. 6280/S. 3607, the Access to Genetic Counselor Services Act, provisions relating to Medicare coverage of genetic counselor services; H.R. 5582/S. 2355, the Patients Deserve Price Tags Act, provisions relating to lab test price transparency; S. 3315, the Health Care Cybersecurity and Resiliency Act, provisions relating to cybersecurity; Federal policy relating to access to mandatory code sets for administrative transactions; Federal policy relating to oversight of laboratory-developed tests; and Federal policy relating to supply chain issues affecting pre-clinical biomedical research for drug development.

Healthcare issues related to clinical laboratories; H.R. 5269/S. 2761,the Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act, provisions relating to reform of Medicare reimbursement for clinical laboratory services under Section 216 of the Protecting Access to Medicare Act, Pub. L. 113-93; H.R. 5582/S. 2355, the Patients Deserve Price Tags Act, and H.R. 9393, the Lower Costs, More Transparency Act, provisions relating to lab test price transparency; H.R. 8500, the Timely Access to Coverage Decisions Act, provisions relating to establishment of standards for Medicare local coverage decisions; H.R. 8890, the Enhancing Clinical Laboratory Innovation and Access (Enhancing CLIA) Act, provisions relating to oversight of laboratory-developed tests; H.R. 9061, the Preeclampsia Risk Evaluation and Evidence-based Management through Personalized Testing (PREEMPT) Act, provisions relating to Medicaid coverage of preeclampsia screening tests; H.R. 8413, the Securing and Establishing Consumer Uniform Rights and Enforcement over Data (SECURE Data) Act, provisions relating to privacy of health care data; A draft of the AI Workforce Assessment and Research (AWARE) Act, provisions relating to disclosure of information on the use and impact of artificial intelligence in employment matters; A draft of the Great American AI Act, provisions relating to regulation of artificial intelligence; Federal policy relating to oversight of laboratory benefit managers; Federal policy relating to access to mandatory code sets for administrative transactions; and Federal policy relating to supply chain issues affecting pre-clinical biomedical research for drug development.

Healthcare issues related to clinical laboratories; H.R. 5269/S. 2761,the Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act, provisions relating to reform of Medicare reimbursement for clinical laboratory services under Section 216 of the Protecting Access to Medicare Act, Pub. L. 113-93; H.R. 5582/S. 2355, the Patients Deserve Price Tags Act, and H.R. 9393, the Lower Costs, More Transparency Act, provisions relating to lab test price transparency; H.R. 8500, the Timely Access to Coverage Decisions Act, provisions relating to establishment of standards for Medicare local coverage decisions; H.R. 8890, the Enhancing Clinical Laboratory Innovation and Access (Enhancing CLIA) Act, provisions relating to oversight of laboratory-developed tests; H.R. 9061, the Preeclampsia Risk Evaluation and Evidence-based Management through Personalized Testing (PREEMPT) Act, provisions relating to Medicaid coverage of preeclampsia screening tests; H.R. 8413, the Securing and Establishing Consumer Uniform Rights and Enforcement over Data (SECURE Data) Act, provisions relating to privacy of health care data; A draft of the AI Workforce Assessment and Research (AWARE) Act, provisions relating to disclosure of information on the use and impact of artificial intelligence in employment matters; A draft of the Great American AI Act, provisions relating to regulation of artificial intelligence; Federal policy relating to oversight of laboratory benefit managers; Federal policy relating to access to mandatory code sets for administrative transactions; and Federal policy relating to supply chain issues affecting pre-clinical biomedical research for drug development.

Healthcare issues related to clinical laboratories; H.R. 5269/S. 2761,the Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act, provisions relating to reform of Medicare reimbursement for clinical laboratory services under Section 216 of the Protecting Access to Medicare Act, Pub. L. 113-93; H.R. 5582/S. 2355, the Patients Deserve Price Tags Act, H.R. 9393, the Lower Costs, More Transparency Act, and H.R. 9645, the Health Care Price Certainty for All Americans Act, provisions relating to lab test price transparency; H.R. 9117, the Clear Healthcare Expense Cost Knowledge (CHECK) Act, provisions relating to administrative service provider price transparency and itemized patient billing; S. 3097, the Health Information Privacy Reform Act, provision relating to privacy of health data; H.R. 8500, the Timely Access to Coverage Decisions Act, provisions relating to establishment of standards for Medicare local coverage decisions; H.R. 8890, the Enhancing Clinical Laboratory Innovation and Access (Enhancing CLIA) Act, provisions relating to oversight of laboratory-developed tests; H.R. 6130/S. 3267, the Alzheimers Screening and Prevention (ASAP) Act, provisions relating to Medicare coverage of blood-based dementia screening tests; H.R. 5444, the Medical Laboratory Personnel Shortage Relief Act, provisions relating to amending the Public Health Service Act to address the shortage of medical laboratory personnel; Federal policy relating to prior authorization and oversight of laboratory benefit managers; Federal policy relating to access to mandatory code sets for administrative transactions; and Federal policy relating to supply chain issues affecting pre-clinical biomedical research for drug development.

Report language accompanying H.R. 8646, the Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2027, provisions relating to oversight of laboratory-developed tests.

Healthcare issues related to clinical laboratories; H.R. 5269/S. 2761,the Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act, provisions relating to reform of Medicare reimbursement for clinical laboratory services under Section 216 of the Protecting Access to Medicare Act, Pub. L. 113-93; H.R. 5582/S. 2355, the Patients Deserve Price Tags Act, and H.R. 9393, the Lower Costs, More Transparency Act, provisions relating to lab test price transparency; H.R. 8500, the Timely Access to Coverage Decisions Act, provisions relating to establishment of standards for Medicare local coverage decisions; H.R. 8890, the Enhancing Clinical Laboratory Innovation and Access (Enhancing CLIA) Act, provisions relating to oversight of laboratory-developed tests; H.R. 9061, the Preeclampsia Risk Evaluation and Evidence-based Management through Personalized Testing (PREEMPT) Act, provisions relating to Medicaid coverage of preeclampsia screening tests; H.R. 8413, the Securing and Establishing Consumer Uniform Rights and Enforcement over Data (SECURE Data) Act, provisions relating to privacy of health care data; A draft of the AI Workforce Assessment and Research (AWARE) Act, provisions relating to disclosure of information on the use and impact of artificial intelligence in employment matters; A draft of the Great American AI Act, provisions relating to regulation of artificial intelligence; Federal policy relating to oversight of laboratory benefit managers; Federal policy relating to access to mandatory code sets for administrative transactions; and Federal policy relating to supply chain issues affecting pre-clinical biomedical research for drug development.

Healthcare issues related to clinical laboratories; H.R. 5269/S. 2761,the Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act, provisions relating to reform of Medicare reimbursement for clinical laboratory services under Section 216 of the Protecting Access to Medicare Act, Pub. L. 113-93; H.R. 5582/S. 2355, the Patients Deserve Price Tags Act, H.R. 9393, the Lower Costs, More Transparency Act, and H.R. 9645, the Health Care Price Certainty for All Americans Act, provisions relating to lab test price transparency; H.R. 9117, the Clear Healthcare Expense Cost Knowledge (CHECK) Act, provisions relating to administrative service provider price transparency and itemized patient billing; S. 3097, the Health Information Privacy Reform Act, provision relating to privacy of health data; H.R. 8500, the Timely Access to Coverage Decisions Act, provisions relating to establishment of standards for Medicare local coverage decisions; H.R. 8890, the Enhancing Clinical Laboratory Innovation and Access (Enhancing CLIA) Act, provisions relating to oversight of laboratory-developed tests; H.R. 6130/S. 3267, the Alzheimers Screening and Prevention (ASAP) Act, provisions relating to Medicare coverage of blood-based dementia screening tests; H.R. 5444, the Medical Laboratory Personnel Shortage Relief Act, provisions relating to amending the Public Health Service Act to address the shortage of medical laboratory personnel; Federal policy relating to prior authorization and oversight of laboratory benefit managers; Federal policy relating to access to mandatory code sets for administrative transactions; and Federal policy relating to supply chain issues affecting pre-clinical biomedical research for drug development.

Healthcare issues related to clinical laboratories; H.R. 5269/S. 2761,the Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act, provisions relating to reform of Medicare reimbursement for clinical laboratory services under Section 216 of the Protecting Access to Medicare Act, Pub. L. 113-93; H.R. 5582/S. 2355, the Patients Deserve Price Tags Act, and H.R. 9393, the Lower Costs, More Transparency Act, provisions relating to lab test price transparency; H.R. 8500, the Timely Access to Coverage Decisions Act, provisions relating to establishment of standards for Medicare local coverage decisions; H.R. 8890, the Enhancing Clinical Laboratory Innovation and Access (Enhancing CLIA) Act, provisions relating to oversight of laboratory-developed tests; H.R. 9061, the Preeclampsia Risk Evaluation and Evidence-based Management through Personalized Testing (PREEMPT) Act, provisions relating to Medicaid coverage of preeclampsia screening tests; H.R. 8413, the Securing and Establishing Consumer Uniform Rights and Enforcement over Data (SECURE Data) Act, provisions relating to privacy of health care data; A draft of the AI Workforce Assessment and Research (AWARE) Act, provisions relating to disclosure of information on the use and impact of artificial intelligence in employment matters; A draft of the Great American AI Act, provisions relating to regulation of artificial intelligence; Federal policy relating to oversight of laboratory benefit managers; Federal policy relating to access to mandatory code sets for administrative transactions; and Federal policy relating to supply chain issues affecting pre-clinical biomedical research for drug development.

Healthcare issues related to clinical laboratories; H.R. 5269/S. 2761,the Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act, provisions relating to reform of Medicare reimbursement for clinical laboratory services under Section 216 of the Protecting Access to Medicare Act, Pub. L. 113-93; H.R. 5582/S. 2355, the Patients Deserve Price Tags Act, H.R. 9393, the Lower Costs, More Transparency Act, and H.R. 9645, the Health Care Price Certainty for All Americans Act, provisions relating to lab test price transparency; H.R. 9117, the Clear Healthcare Expense Cost Knowledge (CHECK) Act, provisions relating to administrative service provider price transparency and itemized patient billing; S. 3097, the Health Information Privacy Reform Act, provision relating to privacy of health data; H.R. 8500, the Timely Access to Coverage Decisions Act, provisions relating to establishment of standards for Medicare local coverage decisions; H.R. 8890, the Enhancing Clinical Laboratory Innovation and Access (Enhancing CLIA) Act, provisions relating to oversight of laboratory-developed tests; H.R. 6130/S. 3267, the Alzheimers Screening and Prevention (ASAP) Act, provisions relating to Medicare coverage of blood-based dementia screening tests; H.R. 5444, the Medical Laboratory Personnel Shortage Relief Act, provisions relating to amending the Public Health Service Act to address the shortage of medical laboratory personnel; Federal policy relating to prior authorization and oversight of laboratory benefit managers; Federal policy relating to access to mandatory code sets for administrative transactions; and Federal policy relating to supply chain issues affecting pre-clinical biomedical research for drug development.

Healthcare issues related to clinical laboratories; H.R. 5269/S. 2761,the Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act, provisions relating to reform of Medicare reimbursement for clinical laboratory services under Section 216 of the Protecting Access to Medicare Act, Pub. L. 113-93; H.R. 5582/S. 2355, the Patients Deserve Price Tags Act, H.R. 9393, the Lower Costs, More Transparency Act, and H.R. 9645, the Health Care Price Certainty for All Americans Act, provisions relating to lab test price transparency; H.R. 9117, the Clear Healthcare Expense Cost Knowledge (CHECK) Act, provisions relating to administrative service provider price transparency and itemized patient billing; S. 3097, the Health Information Privacy Reform Act, provision relating to privacy of health data; H.R. 8500, the Timely Access to Coverage Decisions Act, provisions relating to establishment of standards for Medicare local coverage decisions; H.R. 8890, the Enhancing Clinical Laboratory Innovation and Access (Enhancing CLIA) Act, provisions relating to oversight of laboratory-developed tests; H.R. 6130/S. 3267, the Alzheimers Screening and Prevention (ASAP) Act, provisions relating to Medicare coverage of blood-based dementia screening tests; H.R. 5444, the Medical Laboratory Personnel Shortage Relief Act, provisions relating to amending the Public Health Service Act to address the shortage of medical laboratory personnel; Federal policy relating to prior authorization and oversight of laboratory benefit managers; Federal policy relating to access to mandatory code sets for administrative transactions; and Federal policy relating to supply chain issues affecting pre-clinical biomedical research for drug development.

Healthcare issues related to clinical laboratories; H.R. 5269/S. 2761,the Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act, provisions relating to reform of Medicare reimbursement for clinical laboratory services under Section 216 of the Protecting Access to Medicare Act, Pub. L. 113-93; H.R. 5582/S. 2355, the Patients Deserve Price Tags Act, and H.R. 9393, the Lower Costs, More Transparency Act, provisions relating to lab test price transparency; H.R. 8500, the Timely Access to Coverage Decisions Act, provisions relating to establishment of standards for Medicare local coverage decisions; H.R. 8890, the Enhancing Clinical Laboratory Innovation and Access (Enhancing CLIA) Act, provisions relating to oversight of laboratory-developed tests; H.R. 9061, the Preeclampsia Risk Evaluation and Evidence-based Management through Personalized Testing (PREEMPT) Act, provisions relating to Medicaid coverage of preeclampsia screening tests; H.R. 8413, the Securing and Establishing Consumer Uniform Rights and Enforcement over Data (SECURE Data) Act, provisions relating to privacy of health care data; A draft of the AI Workforce Assessment and Research (AWARE) Act, provisions relating to disclosure of information on the use and impact of artificial intelligence in employment matters; A draft of the Great American AI Act, provisions relating to regulation of artificial intelligence; Federal policy relating to oversight of laboratory benefit managers; Federal policy relating to access to mandatory code sets for administrative transactions; and Federal policy relating to supply chain issues affecting pre-clinical biomedical research for drug development.

Healthcare issues related to clinical laboratories; H.R. 5269/S. 2761,the Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act, provisions relating to reform of Medicare reimbursement for clinical laboratory services under Section 216 of the Protecting Access to Medicare Act, Pub. L. 113-93; H.R. 5582/S. 2355, the Patients Deserve Price Tags Act, H.R. 9393, the Lower Costs, More Transparency Act, and H.R. 9645, the Health Care Price Certainty for All Americans Act, provisions relating to lab test price transparency; H.R. 9117, the Clear Healthcare Expense Cost Knowledge (CHECK) Act, provisions relating to administrative service provider price transparency and itemized patient billing; S. 3097, the Health Information Privacy Reform Act, provision relating to privacy of health data; H.R. 8500, the Timely Access to Coverage Decisions Act, provisions relating to establishment of standards for Medicare local coverage decisions; H.R. 8890, the Enhancing Clinical Laboratory Innovation and Access (Enhancing CLIA) Act, provisions relating to oversight of laboratory-developed tests; H.R. 6130/S. 3267, the Alzheimers Screening and Prevention (ASAP) Act, provisions relating to Medicare coverage of blood-based dementia screening tests; H.R. 5444, the Medical Laboratory Personnel Shortage Relief Act, provisions relating to amending the Public Health Service Act to address the shortage of medical laboratory personnel; Federal policy relating to prior authorization and oversight of laboratory benefit managers; Federal policy relating to access to mandatory code sets for administrative transactions; and Federal policy relating to supply chain issues affecting pre-clinical biomedical research for drug development.

Healthcare issues related to clinical laboratories; H.R. 5269/S. 2761,the Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act, provisions relating to reform of Medicare reimbursement for clinical laboratory services under Section 216 of the Protecting Access to Medicare Act, Pub. L. 113-93; H.R. 5582/S. 2355, the Patients Deserve Price Tags Act, H.R. 9393, the Lower Costs, More Transparency Act, and H.R. 9645, the Health Care Price Certainty for All Americans Act, provisions relating to lab test price transparency; H.R. 9117, the Clear Healthcare Expense Cost Knowledge (CHECK) Act, provisions relating to administrative service provider price transparency and itemized patient billing; S. 3097, the Health Information Privacy Reform Act, provision relating to privacy of health data; H.R. 8500, the Timely Access to Coverage Decisions Act, provisions relating to establishment of standards for Medicare local coverage decisions; H.R. 8890, the Enhancing Clinical Laboratory Innovation and Access (Enhancing CLIA) Act, provisions relating to oversight of laboratory-developed tests; H.R. 6130/S. 3267, the Alzheimers Screening and Prevention (ASAP) Act, provisions relating to Medicare coverage of blood-based dementia screening tests; H.R. 5444, the Medical Laboratory Personnel Shortage Relief Act, provisions relating to amending the Public Health Service Act to address the shortage of medical laboratory personnel; Federal policy relating to prior authorization and oversight of laboratory benefit managers; Federal policy relating to access to mandatory code sets for administrative transactions; and Federal policy relating to supply chain issues affecting pre-clinical biomedical research for drug development.

Healthcare issues related to clinical laboratories; H.R. 5269/S. 2761,the Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act, and Section 6226 of H.R. 7148, the Consolidated Appropriations Act, 2026, Pub. L. 119-75, provisions relating to reform of Medicare reimbursement for clinical laboratory services under Section 216 of the Protecting Access to Medicare Act, Pub. L. 113-93; H.R. 6280/S. 3607, the Access to Genetic Counselor Services Act, provisions relating to Medicare coverage of genetic counselor services; H.R. 5582/S. 2355, the Patients Deserve Price Tags Act, provisions relating to lab test price transparency; S. 3315, the Health Care Cybersecurity and Resiliency Act, provisions relating to cybersecurity; Federal policy relating to access to mandatory code sets for administrative transactions; Federal policy relating to oversight of laboratory-developed tests; and Federal policy relating to supply chain issues affecting pre-clinical biomedical research for drug development.

Healthcare issues related to clinical laboratories; H.R. 5269/S. 2761,the Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act, provisions relating to reform of Medicare reimbursement for clinical laboratory services under Section 216 of the Protecting Access to Medicare Act, Pub. L. 113-93; H.R. 5582/S. 2355, the Patients Deserve Price Tags Act, and H.R. 9393, the Lower Costs, More Transparency Act, provisions relating to lab test price transparency; H.R. 8500, the Timely Access to Coverage Decisions Act, provisions relating to establishment of standards for Medicare local coverage decisions; H.R. 8890, the Enhancing Clinical Laboratory Innovation and Access (Enhancing CLIA) Act, provisions relating to oversight of laboratory-developed tests; H.R. 9061, the Preeclampsia Risk Evaluation and Evidence-based Management through Personalized Testing (PREEMPT) Act, provisions relating to Medicaid coverage of preeclampsia screening tests; H.R. 8413, the Securing and Establishing Consumer Uniform Rights and Enforcement over Data (SECURE Data) Act, provisions relating to privacy of health care data; A draft of the AI Workforce Assessment and Research (AWARE) Act, provisions relating to disclosure of information on the use and impact of artificial intelligence in employment matters; A draft of the Great American AI Act, provisions relating to regulation of artificial intelligence; Federal policy relating to oversight of laboratory benefit managers; Federal policy relating to access to mandatory code sets for administrative transactions; and Federal policy relating to supply chain issues affecting pre-clinical biomedical research for drug development.

Healthcare issues related to clinical laboratories; H.R. 5269/S. 2761,the Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act, provisions relating to reform of Medicare reimbursement for clinical laboratory services under Section 216 of the Protecting Access to Medicare Act, Pub. L. 113-93; H.R. 5582/S. 2355, the Patients Deserve Price Tags Act, and H.R. 9393, the Lower Costs, More Transparency Act, provisions relating to lab test price transparency; H.R. 8500, the Timely Access to Coverage Decisions Act, provisions relating to establishment of standards for Medicare local coverage decisions; H.R. 8890, the Enhancing Clinical Laboratory Innovation and Access (Enhancing CLIA) Act, provisions relating to oversight of laboratory-developed tests; H.R. 9061, the Preeclampsia Risk Evaluation and Evidence-based Management through Personalized Testing (PREEMPT) Act, provisions relating to Medicaid coverage of preeclampsia screening tests; H.R. 8413, the Securing and Establishing Consumer Uniform Rights and Enforcement over Data (SECURE Data) Act, provisions relating to privacy of health care data; A draft of the AI Workforce Assessment and Research (AWARE) Act, provisions relating to disclosure of information on the use and impact of artificial intelligence in employment matters; A draft of the Great American AI Act, provisions relating to regulation of artificial intelligence; Federal policy relating to oversight of laboratory benefit managers; Federal policy relating to access to mandatory code sets for administrative transactions; and Federal policy relating to supply chain issues affecting pre-clinical biomedical research for drug development.

Healthcare issues related to clinical laboratories; H.R. 5269/S. 2761,the Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act, provisions relating to reform of Medicare reimbursement for clinical laboratory services under Section 216 of the Protecting Access to Medicare Act, Pub. L. 113-93; H.R. 5582/S. 2355, the Patients Deserve Price Tags Act, H.R. 9393, the Lower Costs, More Transparency Act, and H.R. 9645, the Health Care Price Certainty for All Americans Act, provisions relating to lab test price transparency; H.R. 9117, the Clear Healthcare Expense Cost Knowledge (CHECK) Act, provisions relating to administrative service provider price transparency and itemized patient billing; S. 3097, the Health Information Privacy Reform Act, provision relating to privacy of health data; H.R. 8500, the Timely Access to Coverage Decisions Act, provisions relating to establishment of standards for Medicare local coverage decisions; H.R. 8890, the Enhancing Clinical Laboratory Innovation and Access (Enhancing CLIA) Act, provisions relating to oversight of laboratory-developed tests; H.R. 6130/S. 3267, the Alzheimers Screening and Prevention (ASAP) Act, provisions relating to Medicare coverage of blood-based dementia screening tests; H.R. 5444, the Medical Laboratory Personnel Shortage Relief Act, provisions relating to amending the Public Health Service Act to address the shortage of medical laboratory personnel; Federal policy relating to prior authorization and oversight of laboratory benefit managers; Federal policy relating to access to mandatory code sets for administrative transactions; and Federal policy relating to supply chain issues affecting pre-clinical biomedical research for drug development.

Healthcare issues related to clinical laboratories; H.R. 5269/S. 2761,the Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act, and Section 6226 of H.R. 7148, the Consolidated Appropriations Act, 2026, Pub. L. 119-75, provisions relating to reform of Medicare reimbursement for clinical laboratory services under Section 216 of the Protecting Access to Medicare Act, Pub. L. 113-93; H.R. 6280/S. 3607, the Access to Genetic Counselor Services Act, provisions relating to Medicare coverage of genetic counselor services; H.R. 5582/S. 2355, the Patients Deserve Price Tags Act, provisions relating to lab test price transparency; S. 3315, the Health Care Cybersecurity and Resiliency Act, provisions relating to cybersecurity; Federal policy relating to access to mandatory code sets for administrative transactions; Federal policy relating to oversight of laboratory-developed tests; and Federal policy relating to supply chain issues affecting pre-clinical biomedical research for drug development.

Healthcare issues related to clinical laboratories; H.R. 5269/S. 2761,the Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act, provisions relating to reform of Medicare reimbursement for clinical laboratory services under Section 216 of the Protecting Access to Medicare Act, Pub. L. 113-93; H.R. 5582/S. 2355, the Patients Deserve Price Tags Act, H.R. 9393, the Lower Costs, More Transparency Act, and H.R. 9645, the Health Care Price Certainty for All Americans Act, provisions relating to lab test price transparency; H.R. 9117, the Clear Healthcare Expense Cost Knowledge (CHECK) Act, provisions relating to administrative service provider price transparency and itemized patient billing; S. 3097, the Health Information Privacy Reform Act, provision relating to privacy of health data; H.R. 8500, the Timely Access to Coverage Decisions Act, provisions relating to establishment of standards for Medicare local coverage decisions; H.R. 8890, the Enhancing Clinical Laboratory Innovation and Access (Enhancing CLIA) Act, provisions relating to oversight of laboratory-developed tests; H.R. 6130/S. 3267, the Alzheimers Screening and Prevention (ASAP) Act, provisions relating to Medicare coverage of blood-based dementia screening tests; H.R. 5444, the Medical Laboratory Personnel Shortage Relief Act, provisions relating to amending the Public Health Service Act to address the shortage of medical laboratory personnel; Federal policy relating to prior authorization and oversight of laboratory benefit managers; Federal policy relating to access to mandatory code sets for administrative transactions; and Federal policy relating to supply chain issues affecting pre-clinical biomedical research for drug development.

Healthcare issues related to clinical laboratories; H.R. 5269/S. 2761,the Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act, provisions relating to reform of Medicare reimbursement for clinical laboratory services under Section 216 of the Protecting Access to Medicare Act, Pub. L. 113-93; H.R. 5582/S. 2355, the Patients Deserve Price Tags Act, H.R. 9393, the Lower Costs, More Transparency Act, and H.R. 9645, the Health Care Price Certainty for All Americans Act, provisions relating to lab test price transparency; H.R. 9117, the Clear Healthcare Expense Cost Knowledge (CHECK) Act, provisions relating to administrative service provider price transparency and itemized patient billing; S. 3097, the Health Information Privacy Reform Act, provision relating to privacy of health data; H.R. 8500, the Timely Access to Coverage Decisions Act, provisions relating to establishment of standards for Medicare local coverage decisions; H.R. 8890, the Enhancing Clinical Laboratory Innovation and Access (Enhancing CLIA) Act, provisions relating to oversight of laboratory-developed tests; H.R. 6130/S. 3267, the Alzheimers Screening and Prevention (ASAP) Act, provisions relating to Medicare coverage of blood-based dementia screening tests; H.R. 5444, the Medical Laboratory Personnel Shortage Relief Act, provisions relating to amending the Public Health Service Act to address the shortage of medical laboratory personnel; Federal policy relating to prior authorization and oversight of laboratory benefit managers; Federal policy relating to access to mandatory code sets for administrative transactions; and Federal policy relating to supply chain issues affecting pre-clinical biomedical research for drug development.

Healthcare issues related to clinical laboratories; H.R. 5269/S. 2761,the Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act, and Section 6226 of H.R. 7148, the Consolidated Appropriations Act, 2026, Pub. L. 119-75, provisions relating to reform of Medicare reimbursement for clinical laboratory services under Section 216 of the Protecting Access to Medicare Act, Pub. L. 113-93; H.R. 6280/S. 3607, the Access to Genetic Counselor Services Act, provisions relating to Medicare coverage of genetic counselor services; H.R. 5582/S. 2355, the Patients Deserve Price Tags Act, provisions relating to lab test price transparency; S. 3315, the Health Care Cybersecurity and Resiliency Act, provisions relating to cybersecurity; Federal policy relating to access to mandatory code sets for administrative transactions; Federal policy relating to oversight of laboratory-developed tests; and Federal policy relating to supply chain issues affecting pre-clinical biomedical research for drug development.

Healthcare issues related to clinical laboratories; H.R. 5269/S. 2761,the Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act, and Section 6226 of H.R. 7148, the Consolidated Appropriations Act, 2026, Pub. L. 119-75, provisions relating to reform of Medicare reimbursement for clinical laboratory services under Section 216 of the Protecting Access to Medicare Act, Pub. L. 113-93; H.R. 6280/S. 3607, the Access to Genetic Counselor Services Act, provisions relating to Medicare coverage of genetic counselor services; H.R. 5582/S. 2355, the Patients Deserve Price Tags Act, provisions relating to lab test price transparency; S. 3315, the Health Care Cybersecurity and Resiliency Act, provisions relating to cybersecurity; Federal policy relating to access to mandatory code sets for administrative transactions; Federal policy relating to oversight of laboratory-developed tests; and Federal policy relating to supply chain issues affecting pre-clinical biomedical research for drug development.

Healthcare issues related to clinical laboratories; H.R. 5269/S. 2761,the Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act, provisions relating to reform of Medicare reimbursement for clinical laboratory services under Section 216 of the Protecting Access to Medicare Act, Pub. L. 113-93; Federal policy relating to oversight of laboratory-developed tests; Section 71120 of H.R. 1, An Act to provide for reconciliation pursuant to title II of H. Con. Res. 14, provisions relating to modifying cost sharing requirements for certain expansion individuals under the Medicaid program; H.R. 3514/S.1816, the Improving Seniors Timely Access to Care Act, provisions relating to prior authorization of services to Medicare Advantage beneficiaries; S. 2355, the Patients Deserve Price Tags Act, provisions relating to lab test price transparency; H.R. 5444, the Medical Laboratory Personnel Shortage Relief Act, provisions relating to medical laboratory personnel eligibility for the National Health Service Corps and federal grants for lab personnel training; Federal policy relating to implementation of Medicare reimbursement cuts under the Statutory Pay-As-You-Go Act of 2010, Pub. L. 111-139; and Federal policy related to supply chain issues affecting pre-clinical biomedical research for drug development.

Healthcare issues related to clinical laboratories; H.R. 5269/S. 2761,the Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act, provisions relating to reform of Medicare reimbursement for clinical laboratory services under Section 216 of the Protecting Access to Medicare Act, Pub. L. 113-93; Federal policy relating to oversight of laboratory-developed tests; Section 71120 of H.R. 1, An Act to provide for reconciliation pursuant to title II of H. Con. Res. 14, provisions relating to modifying cost sharing requirements for certain expansion individuals under the Medicaid program; H.R. 3514/S.1816, the Improving Seniors Timely Access to Care Act, provisions relating to prior authorization of services to Medicare Advantage beneficiaries; S. 2355, the Patients Deserve Price Tags Act, provisions relating to lab test price transparency; H.R. 5444, the Medical Laboratory Personnel Shortage Relief Act, provisions relating to medical laboratory personnel eligibility for the National Health Service Corps and federal grants for lab personnel training; Federal policy relating to implementation of Medicare reimbursement cuts under the Statutory Pay-As-You-Go Act of 2010, Pub. L. 111-139; and Federal policy related to supply chain issues affecting pre-clinical biomedical research for drug development.

Sections 70301, 70302, 70412(b), and 70603 of H.R. 1, An Act to provide for reconciliation pursuant to title II of H. Con. Res. 14, provisions relating to extension of bonus depreciation under Internal Revenue Code Section 168(k), immediate deductibility of domestic research and development expenses under Internal Revenue Code Section 174, individual deductibility of employer-funded tuition assistance under Internal Revenue Code Section 127, and executive compensation under Internal Revenue Code Section 162(m), respectively; Title VII, Subtitle A, Chapter 3, Subchapter B of such Act, provisions relating to treatment of tax credits and reporting simplification under international tax law and guidance; and federal policy relating to income tax rates for corporations and income tax deductibility of corporate state and local taxes.

Healthcare issues related to clinical laboratories; Federal policy relating to reform of Medicare reimbursement for clinical laboratory services under Section 216 of the Protecting Access to Medicare Act, Pub. L. 113-93; Federal policy relating to oversight of laboratory-developed tests; Section 71120 of H.R. 1, An Act to provide for reconciliation pursuant to title II of H. Con. Res. 14, provisions relating to modifying cost sharing requirements for certain expansion individuals under the Medicaid program; H.R. 3152/S. 1546, the Patent Eligibility Restoration Act, provisions relating to patent subject matter eligibility; H.R. 3514/S.1816, the Improving Seniors Timely Access to Care Act, provisions relating to prior authorization of services to Medicare Advantage beneficiaries; A draft of the Health Care Price Transparency Act 2.0 and a draft of the PRICE TAGS Act, provisions relating to lab price transparency; A draft of the Correct Coding Improvement Act, provisions relating to laboratory procedure coding edits adopted by CMS under the National Correct Coding Initiative (NCCI), the adoption of Proprietary Laboratory Analysis (PLA) codes, and access to mandatory code sets for administrative transactions; Federal policy related to supply chain issues affecting pre-clinical biomedical research for drug development; and Federal policy related to Medicare coverage of colorectal cancer screening.

Sections 70301, 70302, 70412(b), and 70603 of H.R. 1, An Act to provide for reconciliation pursuant to title II of H. Con. Res. 14, provisions relating to extension of bonus depreciation under Internal Revenue Code Section 168(k), immediate deductibility of domestic research and development expenses under Internal Revenue Code Section 174, individual deductibility of employer-funded tuition assistance under Internal Revenue Code Section 127, and executive compensation under Internal Revenue Code Section 162(m), respectively; Title VII, Subtitle A, Chapter 3, Subchapter B of such Act, provisions relating to treatment of tax credits and reporting simplification under international tax law and guidance; and federal policy relating to income tax rates for corporations and income tax deductibility of corporate state and local taxes.

Sections 70301, 70302, 70412(b), and 70603 of H.R. 1, An Act to provide for reconciliation pursuant to title II of H. Con. Res. 14, provisions relating to extension of bonus depreciation under Internal Revenue Code Section 168(k), immediate deductibility of domestic research and development expenses under Internal Revenue Code Section 174, individual deductibility of employer-funded tuition assistance under Internal Revenue Code Section 127, and executive compensation under Internal Revenue Code Section 162(m), respectively; Title VII, Subtitle A, Chapter 3, Subchapter B of such Act, provisions relating to treatment of tax credits and reporting simplification under international tax law and guidance; and federal policy relating to income tax rates for corporations and income tax deductibility of corporate state and local taxes.

Healthcare issues related to clinical laboratories; Federal policy relating to reform of Medicare reimbursement for clinical laboratory services under Section 216 of the Protecting Access to Medicare Act, Pub. L. 113-93; Federal policy relating to oversight of laboratory-developed tests; Section 71120 of H.R. 1, An Act to provide for reconciliation pursuant to title II of H. Con. Res. 14, provisions relating to modifying cost sharing requirements for certain expansion individuals under the Medicaid program; H.R. 3152/S. 1546, the Patent Eligibility Restoration Act, provisions relating to patent subject matter eligibility; H.R. 3514/S.1816, the Improving Seniors Timely Access to Care Act, provisions relating to prior authorization of services to Medicare Advantage beneficiaries; A draft of the Health Care Price Transparency Act 2.0 and a draft of the PRICE TAGS Act, provisions relating to lab price transparency; A draft of the Correct Coding Improvement Act, provisions relating to laboratory procedure coding edits adopted by CMS under the National Correct Coding Initiative (NCCI), the adoption of Proprietary Laboratory Analysis (PLA) codes, and access to mandatory code sets for administrative transactions; Federal policy related to supply chain issues affecting pre-clinical biomedical research for drug development; and Federal policy related to Medicare coverage of colorectal cancer screening.

Healthcare issues related to clinical laboratories; H.R. 5269/S. 2761,the Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act, provisions relating to reform of Medicare reimbursement for clinical laboratory services under Section 216 of the Protecting Access to Medicare Act, Pub. L. 113-93; Federal policy relating to oversight of laboratory-developed tests; Section 71120 of H.R. 1, An Act to provide for reconciliation pursuant to title II of H. Con. Res. 14, provisions relating to modifying cost sharing requirements for certain expansion individuals under the Medicaid program; H.R. 3514/S.1816, the Improving Seniors Timely Access to Care Act, provisions relating to prior authorization of services to Medicare Advantage beneficiaries; S. 2355, the Patients Deserve Price Tags Act, provisions relating to lab test price transparency; H.R. 5444, the Medical Laboratory Personnel Shortage Relief Act, provisions relating to medical laboratory personnel eligibility for the National Health Service Corps and federal grants for lab personnel training; Federal policy relating to implementation of Medicare reimbursement cuts under the Statutory Pay-As-You-Go Act of 2010, Pub. L. 111-139; and Federal policy related to supply chain issues affecting pre-clinical biomedical research for drug development.

Sections 70301, 70302, 70412(b), and 70603 of H.R. 1, An Act to provide for reconciliation pursuant to title II of H. Con. Res. 14, provisions relating to extension of bonus depreciation under Internal Revenue Code Section 168(k), immediate deductibility of domestic research and development expenses under Internal Revenue Code Section 174, individual deductibility of employer-funded tuition assistance under Internal Revenue Code Section 127, and executive compensation under Internal Revenue Code Section 162(m), respectively; Title VII, Subtitle A, Chapter 3, Subchapter B of such Act, provisions relating to treatment of tax credits and reporting simplification under international tax law and guidance; and federal policy relating to income tax rates for corporations and income tax deductibility of corporate state and local taxes.

Sections 70301, 70302, 70412(b), and 70603 of H.R. 1, An Act to provide for reconciliation pursuant to title II of H. Con. Res. 14, provisions relating to extension of bonus depreciation under Internal Revenue Code Section 168(k), immediate deductibility of domestic research and development expenses under Internal Revenue Code Section 174, individual deductibility of employer-funded tuition assistance under Internal Revenue Code Section 127, and executive compensation under Internal Revenue Code Section 162(m), respectively; Title VII, Subtitle A, Chapter 3, Subchapter B of such Act, provisions relating to treatment of tax credits and reporting simplification under international tax law and guidance; and federal policy relating to income tax rates for corporations and income tax deductibility of corporate state and local taxes.

Sections 70301, 70302, 70412(b), and 70603 of H.R. 1, An Act to provide for reconciliation pursuant to title II of H. Con. Res. 14, provisions relating to extension of bonus depreciation under Internal Revenue Code Section 168(k), immediate deductibility of domestic research and development expenses under Internal Revenue Code Section 174, individual deductibility of employer-funded tuition assistance under Internal Revenue Code Section 127, and executive compensation under Internal Revenue Code Section 162(m), respectively; Title VII, Subtitle A, Chapter 3, Subchapter B of such Act, provisions relating to treatment of tax credits and reporting simplification under international tax law and guidance; and federal policy relating to income tax rates for corporations and income tax deductibility of corporate state and local taxes.

Healthcare issues related to clinical laboratories; H.R. 5269/S. 2761,the Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act, provisions relating to reform of Medicare reimbursement for clinical laboratory services under Section 216 of the Protecting Access to Medicare Act, Pub. L. 113-93; Federal policy relating to oversight of laboratory-developed tests; Section 71120 of H.R. 1, An Act to provide for reconciliation pursuant to title II of H. Con. Res. 14, provisions relating to modifying cost sharing requirements for certain expansion individuals under the Medicaid program; H.R. 3514/S.1816, the Improving Seniors Timely Access to Care Act, provisions relating to prior authorization of services to Medicare Advantage beneficiaries; S. 2355, the Patients Deserve Price Tags Act, provisions relating to lab test price transparency; H.R. 5444, the Medical Laboratory Personnel Shortage Relief Act, provisions relating to medical laboratory personnel eligibility for the National Health Service Corps and federal grants for lab personnel training; Federal policy relating to implementation of Medicare reimbursement cuts under the Statutory Pay-As-You-Go Act of 2010, Pub. L. 111-139; and Federal policy related to supply chain issues affecting pre-clinical biomedical research for drug development.

Healthcare issues related to clinical laboratories; Federal policy relating to reform of Medicare reimbursement for clinical laboratory services under Section 216 of the Protecting Access to Medicare Act, Pub. L. 113-93; Federal policy relating to oversight of laboratory-developed tests; Federal policy relating to Medicaid reimbursement for clinical laboratory services; Federal policy relating to prior authorization of services to Medicare Advantage beneficiaries; Federal policy relating to CDC funding for laboratory test harmonization in the Fiscal Year 2026 Labor-HHS Appropriations bills; H.R. 2471, the Right Drug Dose Now Act, provisions relating to increasing adoption of pharmacogenetic testing; A draft of the Correct Coding Improvement Act, provisions relating to laboratory procedure coding edits adopted by CMS under the National Correct Coding Initiative (NCCI), the adoption of Proprietary Laboratory Analysis (PLA) codes, and access to mandatory code sets for administrative transactions; Federal policy related to supply chain issues affecting pre-clinical biomedical research for drug development; and Federal policy related to Medicare coverage of colorectal cancer screening.

Healthcare issues related to clinical laboratories; Federal policy relating to reform of Medicare reimbursement for clinical laboratory services under Section 216 of the Protecting Access to Medicare Act, Pub. L. 113-93; Federal policy relating to oversight of laboratory-developed tests; Federal policy relating to Medicaid reimbursement for clinical laboratory services; Federal policy relating to prior authorization of services to Medicare Advantage beneficiaries; Federal policy relating to CDC funding for laboratory test harmonization in the Fiscal Year 2026 Labor-HHS Appropriations bills; H.R. 2471, the Right Drug Dose Now Act, provisions relating to increasing adoption of pharmacogenetic testing; A draft of the Correct Coding Improvement Act, provisions relating to laboratory procedure coding edits adopted by CMS under the National Correct Coding Initiative (NCCI), the adoption of Proprietary Laboratory Analysis (PLA) codes, and access to mandatory code sets for administrative transactions; Federal policy related to supply chain issues affecting pre-clinical biomedical research for drug development; and Federal policy related to Medicare coverage of colorectal cancer screening.

Healthcare issues related to clinical laboratories; Federal policy relating to reform of Medicare reimbursement for clinical laboratory services under Section 216 of the Protecting Access to Medicare Act, Pub. L. 113-93; Federal policy relating to oversight of laboratory-developed tests; Section 71120 of H.R. 1, An Act to provide for reconciliation pursuant to title II of H. Con. Res. 14, provisions relating to modifying cost sharing requirements for certain expansion individuals under the Medicaid program; H.R. 3152/S. 1546, the Patent Eligibility Restoration Act, provisions relating to patent subject matter eligibility; H.R. 3514/S.1816, the Improving Seniors Timely Access to Care Act, provisions relating to prior authorization of services to Medicare Advantage beneficiaries; A draft of the Health Care Price Transparency Act 2.0 and a draft of the PRICE TAGS Act, provisions relating to lab price transparency; A draft of the Correct Coding Improvement Act, provisions relating to laboratory procedure coding edits adopted by CMS under the National Correct Coding Initiative (NCCI), the adoption of Proprietary Laboratory Analysis (PLA) codes, and access to mandatory code sets for administrative transactions; Federal policy related to supply chain issues affecting pre-clinical biomedical research for drug development; and Federal policy related to Medicare coverage of colorectal cancer screening.

Healthcare issues related to clinical laboratories; H.R. 5269/S. 2761,the Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act, provisions relating to reform of Medicare reimbursement for clinical laboratory services under Section 216 of the Protecting Access to Medicare Act, Pub. L. 113-93; Federal policy relating to oversight of laboratory-developed tests; Section 71120 of H.R. 1, An Act to provide for reconciliation pursuant to title II of H. Con. Res. 14, provisions relating to modifying cost sharing requirements for certain expansion individuals under the Medicaid program; H.R. 3514/S.1816, the Improving Seniors Timely Access to Care Act, provisions relating to prior authorization of services to Medicare Advantage beneficiaries; S. 2355, the Patients Deserve Price Tags Act, provisions relating to lab test price transparency; H.R. 5444, the Medical Laboratory Personnel Shortage Relief Act, provisions relating to medical laboratory personnel eligibility for the National Health Service Corps and federal grants for lab personnel training; Federal policy relating to implementation of Medicare reimbursement cuts under the Statutory Pay-As-You-Go Act of 2010, Pub. L. 111-139; and Federal policy related to supply chain issues affecting pre-clinical biomedical research for drug development.

Healthcare issues related to clinical laboratories; H.R. 5269/S. 2761,the Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act, provisions relating to reform of Medicare reimbursement for clinical laboratory services under Section 216 of the Protecting Access to Medicare Act, Pub. L. 113-93; Federal policy relating to oversight of laboratory-developed tests; Section 71120 of H.R. 1, An Act to provide for reconciliation pursuant to title II of H. Con. Res. 14, provisions relating to modifying cost sharing requirements for certain expansion individuals under the Medicaid program; H.R. 3514/S.1816, the Improving Seniors Timely Access to Care Act, provisions relating to prior authorization of services to Medicare Advantage beneficiaries; S. 2355, the Patients Deserve Price Tags Act, provisions relating to lab test price transparency; H.R. 5444, the Medical Laboratory Personnel Shortage Relief Act, provisions relating to medical laboratory personnel eligibility for the National Health Service Corps and federal grants for lab personnel training; Federal policy relating to implementation of Medicare reimbursement cuts under the Statutory Pay-As-You-Go Act of 2010, Pub. L. 111-139; and Federal policy related to supply chain issues affecting pre-clinical biomedical research for drug development.

Healthcare issues related to clinical laboratories; Federal policy relating to reform of Medicare reimbursement for clinical laboratory services under Section 216 of the Protecting Access to Medicare Act, Pub. L. 113-93; Federal policy relating to oversight of laboratory-developed tests; Section 71120 of H.R. 1, An Act to provide for reconciliation pursuant to title II of H. Con. Res. 14, provisions relating to modifying cost sharing requirements for certain expansion individuals under the Medicaid program; H.R. 3152/S. 1546, the Patent Eligibility Restoration Act, provisions relating to patent subject matter eligibility; H.R. 3514/S.1816, the Improving Seniors Timely Access to Care Act, provisions relating to prior authorization of services to Medicare Advantage beneficiaries; A draft of the Health Care Price Transparency Act 2.0 and a draft of the PRICE TAGS Act, provisions relating to lab price transparency; A draft of the Correct Coding Improvement Act, provisions relating to laboratory procedure coding edits adopted by CMS under the National Correct Coding Initiative (NCCI), the adoption of Proprietary Laboratory Analysis (PLA) codes, and access to mandatory code sets for administrative transactions; Federal policy related to supply chain issues affecting pre-clinical biomedical research for drug development; and Federal policy related to Medicare coverage of colorectal cancer screening.

Healthcare issues related to clinical laboratories; H.R. 5269/S. 2761,the Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act, and Section 6209 of the Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extension Act, 2026, Pub. L. 119-37, provisions relating to reform of Medicare reimbursement for clinical laboratory services under Section 216 of the Protecting Access to Medicare Act, Pub. L. 113-93; Section 8001 of H.R. 5371, the Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extension Act, 2026, Pub. L. 119-37, provisions relating to implementation of Medicare reimbursement cuts under the Statutory Pay-As-You-Go Act of 2010, Pub. L. 111-139; H.R. 6280, the Access to Genetic Counselor Services Act, provisions relating to Medicare coverage of genetic counselor services; H.R. 5582/S. 2355, the Patients Deserve Price Tags Act, provisions relating to lab test price transparency; H.R. 5454/S. 2879, the Medicare Advantage Prompt Pay Act, and H.R. 4559, the Prompt and Fair Pay Act, provisions relating to prompt payment of Medicare Advantage claims; Federal policy relating to access to mandatory code sets for administrative transactions; Federal policy relating to oversight of laboratory-developed tests; and Federal policy relating to supply chain issues affecting pre-clinical biomedical research for drug development.

Healthcare issues related to clinical laboratories; H.R. 5269/S. 2761,the Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act, and Section 6209 of the Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extension Act, 2026, Pub. L. 119-37, provisions relating to reform of Medicare reimbursement for clinical laboratory services under Section 216 of the Protecting Access to Medicare Act, Pub. L. 113-93; Section 8001 of H.R. 5371, the Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extension Act, 2026, Pub. L. 119-37, provisions relating to implementation of Medicare reimbursement cuts under the Statutory Pay-As-You-Go Act of 2010, Pub. L. 111-139; H.R. 6280, the Access to Genetic Counselor Services Act, provisions relating to Medicare coverage of genetic counselor services; H.R. 5582/S. 2355, the Patients Deserve Price Tags Act, provisions relating to lab test price transparency; H.R. 5454/S. 2879, the Medicare Advantage Prompt Pay Act, and H.R. 4559, the Prompt and Fair Pay Act, provisions relating to prompt payment of Medicare Advantage claims; Federal policy relating to access to mandatory code sets for administrative transactions; Federal policy relating to oversight of laboratory-developed tests; and Federal policy relating to supply chain issues affecting pre-clinical biomedical research for drug development.

Healthcare issues related to clinical laboratories; H.R. 5269/S. 2761,the Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act, and Section 6209 of the Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extension Act, 2026, Pub. L. 119-37, provisions relating to reform of Medicare reimbursement for clinical laboratory services under Section 216 of the Protecting Access to Medicare Act, Pub. L. 113-93; Section 8001 of H.R. 5371, the Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extension Act, 2026, Pub. L. 119-37, provisions relating to implementation of Medicare reimbursement cuts under the Statutory Pay-As-You-Go Act of 2010, Pub. L. 111-139; H.R. 6280, the Access to Genetic Counselor Services Act, provisions relating to Medicare coverage of genetic counselor services; H.R. 5582/S. 2355, the Patients Deserve Price Tags Act, provisions relating to lab test price transparency; H.R. 5454/S. 2879, the Medicare Advantage Prompt Pay Act, and H.R. 4559, the Prompt and Fair Pay Act, provisions relating to prompt payment of Medicare Advantage claims; Federal policy relating to access to mandatory code sets for administrative transactions; Federal policy relating to oversight of laboratory-developed tests; and Federal policy relating to supply chain issues affecting pre-clinical biomedical research for drug development.

Healthcare issues related to clinical laboratories; H.R. 5269/S. 2761,the Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act, provisions relating to reform of Medicare reimbursement for clinical laboratory services under Section 216 of the Protecting Access to Medicare Act, Pub. L. 113-93; Federal policy relating to oversight of laboratory-developed tests; Section 71120 of H.R. 1, An Act to provide for reconciliation pursuant to title II of H. Con. Res. 14, provisions relating to modifying cost sharing requirements for certain expansion individuals under the Medicaid program; H.R. 3514/S.1816, the Improving Seniors Timely Access to Care Act, provisions relating to prior authorization of services to Medicare Advantage beneficiaries; S. 2355, the Patients Deserve Price Tags Act, provisions relating to lab test price transparency; H.R. 5444, the Medical Laboratory Personnel Shortage Relief Act, provisions relating to medical laboratory personnel eligibility for the National Health Service Corps and federal grants for lab personnel training; Federal policy relating to implementation of Medicare reimbursement cuts under the Statutory Pay-As-You-Go Act of 2010, Pub. L. 111-139; and Federal policy related to supply chain issues affecting pre-clinical biomedical research for drug development.

Healthcare issues related to clinical laboratories; H.R. 5269/S. 2761,the Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act, and Section 6209 of the Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extension Act, 2026, Pub. L. 119-37, provisions relating to reform of Medicare reimbursement for clinical laboratory services under Section 216 of the Protecting Access to Medicare Act, Pub. L. 113-93; Section 8001 of H.R. 5371, the Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extension Act, 2026, Pub. L. 119-37, provisions relating to implementation of Medicare reimbursement cuts under the Statutory Pay-As-You-Go Act of 2010, Pub. L. 111-139; H.R. 6280, the Access to Genetic Counselor Services Act, provisions relating to Medicare coverage of genetic counselor services; H.R. 5582/S. 2355, the Patients Deserve Price Tags Act, provisions relating to lab test price transparency; H.R. 5454/S. 2879, the Medicare Advantage Prompt Pay Act, and H.R. 4559, the Prompt and Fair Pay Act, provisions relating to prompt payment of Medicare Advantage claims; Federal policy relating to access to mandatory code sets for administrative transactions; Federal policy relating to oversight of laboratory-developed tests; and Federal policy relating to supply chain issues affecting pre-clinical biomedical research for drug development.

Healthcare issues related to clinical laboratories; H.R. 5269/S. 2761,the Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act, provisions relating to reform of Medicare reimbursement for clinical laboratory services under Section 216 of the Protecting Access to Medicare Act, Pub. L. 113-93; Federal policy relating to oversight of laboratory-developed tests; Section 71120 of H.R. 1, An Act to provide for reconciliation pursuant to title II of H. Con. Res. 14, provisions relating to modifying cost sharing requirements for certain expansion individuals under the Medicaid program; H.R. 3514/S.1816, the Improving Seniors Timely Access to Care Act, provisions relating to prior authorization of services to Medicare Advantage beneficiaries; S. 2355, the Patients Deserve Price Tags Act, provisions relating to lab test price transparency; H.R. 5444, the Medical Laboratory Personnel Shortage Relief Act, provisions relating to medical laboratory personnel eligibility for the National Health Service Corps and federal grants for lab personnel training; Federal policy relating to implementation of Medicare reimbursement cuts under the Statutory Pay-As-You-Go Act of 2010, Pub. L. 111-139; and Federal policy related to supply chain issues affecting pre-clinical biomedical research for drug development.

Healthcare issues related to clinical laboratories; H.R. 5269/S. 2761,the Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act, provisions relating to reform of Medicare reimbursement for clinical laboratory services under Section 216 of the Protecting Access to Medicare Act, Pub. L. 113-93; Federal policy relating to oversight of laboratory-developed tests; Section 71120 of H.R. 1, An Act to provide for reconciliation pursuant to title II of H. Con. Res. 14, provisions relating to modifying cost sharing requirements for certain expansion individuals under the Medicaid program; H.R. 3514/S.1816, the Improving Seniors Timely Access to Care Act, provisions relating to prior authorization of services to Medicare Advantage beneficiaries; S. 2355, the Patients Deserve Price Tags Act, provisions relating to lab test price transparency; H.R. 5444, the Medical Laboratory Personnel Shortage Relief Act, provisions relating to medical laboratory personnel eligibility for the National Health Service Corps and federal grants for lab personnel training; Federal policy relating to implementation of Medicare reimbursement cuts under the Statutory Pay-As-You-Go Act of 2010, Pub. L. 111-139; and Federal policy related to supply chain issues affecting pre-clinical biomedical research for drug development.

Healthcare issues related to clinical laboratories; H.R. 5269/S. 2761,the Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act, provisions relating to reform of Medicare reimbursement for clinical laboratory services under Section 216 of the Protecting Access to Medicare Act, Pub. L. 113-93; Federal policy relating to oversight of laboratory-developed tests; Section 71120 of H.R. 1, An Act to provide for reconciliation pursuant to title II of H. Con. Res. 14, provisions relating to modifying cost sharing requirements for certain expansion individuals under the Medicaid program; H.R. 3514/S.1816, the Improving Seniors Timely Access to Care Act, provisions relating to prior authorization of services to Medicare Advantage beneficiaries; S. 2355, the Patients Deserve Price Tags Act, provisions relating to lab test price transparency; H.R. 5444, the Medical Laboratory Personnel Shortage Relief Act, provisions relating to medical laboratory personnel eligibility for the National Health Service Corps and federal grants for lab personnel training; Federal policy relating to implementation of Medicare reimbursement cuts under the Statutory Pay-As-You-Go Act of 2010, Pub. L. 111-139; and Federal policy related to supply chain issues affecting pre-clinical biomedical research for drug development.

Healthcare issues related to clinical laboratories; H.R. 5269/S. 2761,the Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act, and Section 6209 of the Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extension Act, 2026, Pub. L. 119-37, provisions relating to reform of Medicare reimbursement for clinical laboratory services under Section 216 of the Protecting Access to Medicare Act, Pub. L. 113-93; Section 8001 of H.R. 5371, the Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extension Act, 2026, Pub. L. 119-37, provisions relating to implementation of Medicare reimbursement cuts under the Statutory Pay-As-You-Go Act of 2010, Pub. L. 111-139; H.R. 6280, the Access to Genetic Counselor Services Act, provisions relating to Medicare coverage of genetic counselor services; H.R. 5582/S. 2355, the Patients Deserve Price Tags Act, provisions relating to lab test price transparency; H.R. 5454/S. 2879, the Medicare Advantage Prompt Pay Act, and H.R. 4559, the Prompt and Fair Pay Act, provisions relating to prompt payment of Medicare Advantage claims; Federal policy relating to access to mandatory code sets for administrative transactions; Federal policy relating to oversight of laboratory-developed tests; and Federal policy relating to supply chain issues affecting pre-clinical biomedical research for drug development.

Healthcare issues related to clinical laboratories; H.R. 5269/S. 2761,the Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act, and Section 6209 of the Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extension Act, 2026, Pub. L. 119-37, provisions relating to reform of Medicare reimbursement for clinical laboratory services under Section 216 of the Protecting Access to Medicare Act, Pub. L. 113-93; Section 8001 of H.R. 5371, the Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extension Act, 2026, Pub. L. 119-37, provisions relating to implementation of Medicare reimbursement cuts under the Statutory Pay-As-You-Go Act of 2010, Pub. L. 111-139; H.R. 6280, the Access to Genetic Counselor Services Act, provisions relating to Medicare coverage of genetic counselor services; H.R. 5582/S. 2355, the Patients Deserve Price Tags Act, provisions relating to lab test price transparency; H.R. 5454/S. 2879, the Medicare Advantage Prompt Pay Act, and H.R. 4559, the Prompt and Fair Pay Act, provisions relating to prompt payment of Medicare Advantage claims; Federal policy relating to access to mandatory code sets for administrative transactions; Federal policy relating to oversight of laboratory-developed tests; and Federal policy relating to supply chain issues affecting pre-clinical biomedical research for drug development.

Healthcare issues related to clinical laboratories; H.R. 5269/S. 2761,the Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act, and Section 6209 of the Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extension Act, 2026, Pub. L. 119-37, provisions relating to reform of Medicare reimbursement for clinical laboratory services under Section 216 of the Protecting Access to Medicare Act, Pub. L. 113-93; Section 8001 of H.R. 5371, the Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extension Act, 2026, Pub. L. 119-37, provisions relating to implementation of Medicare reimbursement cuts under the Statutory Pay-As-You-Go Act of 2010, Pub. L. 111-139; H.R. 6280, the Access to Genetic Counselor Services Act, provisions relating to Medicare coverage of genetic counselor services; H.R. 5582/S. 2355, the Patients Deserve Price Tags Act, provisions relating to lab test price transparency; H.R. 5454/S. 2879, the Medicare Advantage Prompt Pay Act, and H.R. 4559, the Prompt and Fair Pay Act, provisions relating to prompt payment of Medicare Advantage claims; Federal policy relating to access to mandatory code sets for administrative transactions; Federal policy relating to oversight of laboratory-developed tests; and Federal policy relating to supply chain issues affecting pre-clinical biomedical research for drug development.

Healthcare issues related to clinical laboratories; H.R. 5269/S. 2761,the Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act, and Section 6209 of the Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extension Act, 2026, Pub. L. 119-37, provisions relating to reform of Medicare reimbursement for clinical laboratory services under Section 216 of the Protecting Access to Medicare Act, Pub. L. 113-93; Section 8001 of H.R. 5371, the Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extension Act, 2026, Pub. L. 119-37, provisions relating to implementation of Medicare reimbursement cuts under the Statutory Pay-As-You-Go Act of 2010, Pub. L. 111-139; H.R. 6280, the Access to Genetic Counselor Services Act, provisions relating to Medicare coverage of genetic counselor services; H.R. 5582/S. 2355, the Patients Deserve Price Tags Act, provisions relating to lab test price transparency; H.R. 5454/S. 2879, the Medicare Advantage Prompt Pay Act, and H.R. 4559, the Prompt and Fair Pay Act, provisions relating to prompt payment of Medicare Advantage claims; Federal policy relating to access to mandatory code sets for administrative transactions; Federal policy relating to oversight of laboratory-developed tests; and Federal policy relating to supply chain issues affecting pre-clinical biomedical research for drug development.

Healthcare issues related to clinical laboratories; H.R. 5269/S. 2761,the Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act, and Section 6209 of the Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extension Act, 2026, Pub. L. 119-37, provisions relating to reform of Medicare reimbursement for clinical laboratory services under Section 216 of the Protecting Access to Medicare Act, Pub. L. 113-93; Section 8001 of H.R. 5371, the Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extension Act, 2026, Pub. L. 119-37, provisions relating to implementation of Medicare reimbursement cuts under the Statutory Pay-As-You-Go Act of 2010, Pub. L. 111-139; H.R. 6280, the Access to Genetic Counselor Services Act, provisions relating to Medicare coverage of genetic counselor services; H.R. 5582/S. 2355, the Patients Deserve Price Tags Act, provisions relating to lab test price transparency; H.R. 5454/S. 2879, the Medicare Advantage Prompt Pay Act, and H.R. 4559, the Prompt and Fair Pay Act, provisions relating to prompt payment of Medicare Advantage claims; Federal policy relating to access to mandatory code sets for administrative transactions; Federal policy relating to oversight of laboratory-developed tests; and Federal policy relating to supply chain issues affecting pre-clinical biomedical research for drug development.

Healthcare issues related to clinical laboratories; H.R. 5269/S. 2761,the Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act, and Section 6209 of the Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extension Act, 2026, Pub. L. 119-37, provisions relating to reform of Medicare reimbursement for clinical laboratory services under Section 216 of the Protecting Access to Medicare Act, Pub. L. 113-93; Section 8001 of H.R. 5371, the Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extension Act, 2026, Pub. L. 119-37, provisions relating to implementation of Medicare reimbursement cuts under the Statutory Pay-As-You-Go Act of 2010, Pub. L. 111-139; H.R. 6280, the Access to Genetic Counselor Services Act, provisions relating to Medicare coverage of genetic counselor services; H.R. 5582/S. 2355, the Patients Deserve Price Tags Act, provisions relating to lab test price transparency; H.R. 5454/S. 2879, the Medicare Advantage Prompt Pay Act, and H.R. 4559, the Prompt and Fair Pay Act, provisions relating to prompt payment of Medicare Advantage claims; Federal policy relating to access to mandatory code sets for administrative transactions; Federal policy relating to oversight of laboratory-developed tests; and Federal policy relating to supply chain issues affecting pre-clinical biomedical research for drug development.

Healthcare issues related to clinical laboratories; Federal policy relating to reform of Medicare reimbursement for clinical laboratory services under Section 216 of the Protecting Access to Medicare Act, Pub. L. 113-93; Federal policy relating to oversight of laboratory-developed tests; Section 71120 of H.R. 1, An Act to provide for reconciliation pursuant to title II of H. Con. Res. 14, provisions relating to modifying cost sharing requirements for certain expansion individuals under the Medicaid program; H.R. 3152/S. 1546, the Patent Eligibility Restoration Act, provisions relating to patent subject matter eligibility; H.R. 3514/S.1816, the Improving Seniors Timely Access to Care Act, provisions relating to prior authorization of services to Medicare Advantage beneficiaries; A draft of the Health Care Price Transparency Act 2.0 and a draft of the PRICE TAGS Act, provisions relating to lab price transparency; A draft of the Correct Coding Improvement Act, provisions relating to laboratory procedure coding edits adopted by CMS under the National Correct Coding Initiative (NCCI), the adoption of Proprietary Laboratory Analysis (PLA) codes, and access to mandatory code sets for administrative transactions; Federal policy related to supply chain issues affecting pre-clinical biomedical research for drug development; and Federal policy related to Medicare coverage of colorectal cancer screening.

Healthcare issues related to clinical laboratories; Federal policy relating to reform of Medicare reimbursement for clinical laboratory services under Section 216 of the Protecting Access to Medicare Act, Pub. L. 113-93; Federal policy relating to oversight of laboratory-developed tests; Section 71120 of H.R. 1, An Act to provide for reconciliation pursuant to title II of H. Con. Res. 14, provisions relating to modifying cost sharing requirements for certain expansion individuals under the Medicaid program; H.R. 3152/S. 1546, the Patent Eligibility Restoration Act, provisions relating to patent subject matter eligibility; H.R. 3514/S.1816, the Improving Seniors Timely Access to Care Act, provisions relating to prior authorization of services to Medicare Advantage beneficiaries; A draft of the Health Care Price Transparency Act 2.0 and a draft of the PRICE TAGS Act, provisions relating to lab price transparency; A draft of the Correct Coding Improvement Act, provisions relating to laboratory procedure coding edits adopted by CMS under the National Correct Coding Initiative (NCCI), the adoption of Proprietary Laboratory Analysis (PLA) codes, and access to mandatory code sets for administrative transactions; Federal policy related to supply chain issues affecting pre-clinical biomedical research for drug development; and Federal policy related to Medicare coverage of colorectal cancer screening.

Healthcare issues related to clinical laboratories; H.R. 5269/S. 2761,the Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act, provisions relating to reform of Medicare reimbursement for clinical laboratory services under Section 216 of the Protecting Access to Medicare Act, Pub. L. 113-93; Federal policy relating to oversight of laboratory-developed tests; Section 71120 of H.R. 1, An Act to provide for reconciliation pursuant to title II of H. Con. Res. 14, provisions relating to modifying cost sharing requirements for certain expansion individuals under the Medicaid program; H.R. 3514/S.1816, the Improving Seniors Timely Access to Care Act, provisions relating to prior authorization of services to Medicare Advantage beneficiaries; S. 2355, the Patients Deserve Price Tags Act, provisions relating to lab test price transparency; H.R. 5444, the Medical Laboratory Personnel Shortage Relief Act, provisions relating to medical laboratory personnel eligibility for the National Health Service Corps and federal grants for lab personnel training; Federal policy relating to implementation of Medicare reimbursement cuts under the Statutory Pay-As-You-Go Act of 2010, Pub. L. 111-139; and Federal policy related to supply chain issues affecting pre-clinical biomedical research for drug development.

Healthcare issues related to clinical laboratories; H.R. 5269/S. 2761,the Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act, provisions relating to reform of Medicare reimbursement for clinical laboratory services under Section 216 of the Protecting Access to Medicare Act, Pub. L. 113-93; Federal policy relating to oversight of laboratory-developed tests; Section 71120 of H.R. 1, An Act to provide for reconciliation pursuant to title II of H. Con. Res. 14, provisions relating to modifying cost sharing requirements for certain expansion individuals under the Medicaid program; H.R. 3514/S.1816, the Improving Seniors Timely Access to Care Act, provisions relating to prior authorization of services to Medicare Advantage beneficiaries; S. 2355, the Patients Deserve Price Tags Act, provisions relating to lab test price transparency; H.R. 5444, the Medical Laboratory Personnel Shortage Relief Act, provisions relating to medical laboratory personnel eligibility for the National Health Service Corps and federal grants for lab personnel training; Federal policy relating to implementation of Medicare reimbursement cuts under the Statutory Pay-As-You-Go Act of 2010, Pub. L. 111-139; and Federal policy related to supply chain issues affecting pre-clinical biomedical research for drug development.

Healthcare issues related to clinical laboratories; H.R. 5269/S. 2761,the Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act, provisions relating to reform of Medicare reimbursement for clinical laboratory services under Section 216 of the Protecting Access to Medicare Act, Pub. L. 113-93; Federal policy relating to oversight of laboratory-developed tests; Section 71120 of H.R. 1, An Act to provide for reconciliation pursuant to title II of H. Con. Res. 14, provisions relating to modifying cost sharing requirements for certain expansion individuals under the Medicaid program; H.R. 3514/S.1816, the Improving Seniors Timely Access to Care Act, provisions relating to prior authorization of services to Medicare Advantage beneficiaries; S. 2355, the Patients Deserve Price Tags Act, provisions relating to lab test price transparency; H.R. 5444, the Medical Laboratory Personnel Shortage Relief Act, provisions relating to medical laboratory personnel eligibility for the National Health Service Corps and federal grants for lab personnel training; Federal policy relating to implementation of Medicare reimbursement cuts under the Statutory Pay-As-You-Go Act of 2010, Pub. L. 111-139; and Federal policy related to supply chain issues affecting pre-clinical biomedical research for drug development.

Healthcare issues related to clinical laboratories; H.R. 5269/S. 2761,the Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act, provisions relating to reform of Medicare reimbursement for clinical laboratory services under Section 216 of the Protecting Access to Medicare Act, Pub. L. 113-93; Federal policy relating to oversight of laboratory-developed tests; Section 71120 of H.R. 1, An Act to provide for reconciliation pursuant to title II of H. Con. Res. 14, provisions relating to modifying cost sharing requirements for certain expansion individuals under the Medicaid program; H.R. 3514/S.1816, the Improving Seniors Timely Access to Care Act, provisions relating to prior authorization of services to Medicare Advantage beneficiaries; S. 2355, the Patients Deserve Price Tags Act, provisions relating to lab test price transparency; H.R. 5444, the Medical Laboratory Personnel Shortage Relief Act, provisions relating to medical laboratory personnel eligibility for the National Health Service Corps and federal grants for lab personnel training; Federal policy relating to implementation of Medicare reimbursement cuts under the Statutory Pay-As-You-Go Act of 2010, Pub. L. 111-139; and Federal policy related to supply chain issues affecting pre-clinical biomedical research for drug development.

Healthcare issues related to clinical laboratories; H.R. 5269/S. 2761,the Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act, and Section 6209 of the Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extension Act, 2026, Pub. L. 119-37, provisions relating to reform of Medicare reimbursement for clinical laboratory services under Section 216 of the Protecting Access to Medicare Act, Pub. L. 113-93; Section 8001 of H.R. 5371, the Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extension Act, 2026, Pub. L. 119-37, provisions relating to implementation of Medicare reimbursement cuts under the Statutory Pay-As-You-Go Act of 2010, Pub. L. 111-139; H.R. 6280, the Access to Genetic Counselor Services Act, provisions relating to Medicare coverage of genetic counselor services; H.R. 5582/S. 2355, the Patients Deserve Price Tags Act, provisions relating to lab test price transparency; H.R. 5454/S. 2879, the Medicare Advantage Prompt Pay Act, and H.R. 4559, the Prompt and Fair Pay Act, provisions relating to prompt payment of Medicare Advantage claims; Federal policy relating to access to mandatory code sets for administrative transactions; Federal policy relating to oversight of laboratory-developed tests; and Federal policy relating to supply chain issues affecting pre-clinical biomedical research for drug development.

Healthcare issues related to clinical laboratories; H.R. 5269/S. 2761,the Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act, and Section 6209 of the Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extension Act, 2026, Pub. L. 119-37, provisions relating to reform of Medicare reimbursement for clinical laboratory services under Section 216 of the Protecting Access to Medicare Act, Pub. L. 113-93; Section 8001 of H.R. 5371, the Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extension Act, 2026, Pub. L. 119-37, provisions relating to implementation of Medicare reimbursement cuts under the Statutory Pay-As-You-Go Act of 2010, Pub. L. 111-139; H.R. 6280, the Access to Genetic Counselor Services Act, provisions relating to Medicare coverage of genetic counselor services; H.R. 5582/S. 2355, the Patients Deserve Price Tags Act, provisions relating to lab test price transparency; H.R. 5454/S. 2879, the Medicare Advantage Prompt Pay Act, and H.R. 4559, the Prompt and Fair Pay Act, provisions relating to prompt payment of Medicare Advantage claims; Federal policy relating to access to mandatory code sets for administrative transactions; Federal policy relating to oversight of laboratory-developed tests; and Federal policy relating to supply chain issues affecting pre-clinical biomedical research for drug development.

Healthcare issues related to clinical laboratories; H.R. 5269/S. 2761,the Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act, and Section 6209 of the Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extension Act, 2026, Pub. L. 119-37, provisions relating to reform of Medicare reimbursement for clinical laboratory services under Section 216 of the Protecting Access to Medicare Act, Pub. L. 113-93; Section 8001 of H.R. 5371, the Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extension Act, 2026, Pub. L. 119-37, provisions relating to implementation of Medicare reimbursement cuts under the Statutory Pay-As-You-Go Act of 2010, Pub. L. 111-139; H.R. 6280, the Access to Genetic Counselor Services Act, provisions relating to Medicare coverage of genetic counselor services; H.R. 5582/S. 2355, the Patients Deserve Price Tags Act, provisions relating to lab test price transparency; H.R. 5454/S. 2879, the Medicare Advantage Prompt Pay Act, and H.R. 4559, the Prompt and Fair Pay Act, provisions relating to prompt payment of Medicare Advantage claims; Federal policy relating to access to mandatory code sets for administrative transactions; Federal policy relating to oversight of laboratory-developed tests; and Federal policy relating to supply chain issues affecting pre-clinical biomedical research for drug development.

Healthcare issues related to clinical laboratories; H.R. 5269/S. 2761,the Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act, and Section 6209 of the Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extension Act, 2026, Pub. L. 119-37, provisions relating to reform of Medicare reimbursement for clinical laboratory services under Section 216 of the Protecting Access to Medicare Act, Pub. L. 113-93; Section 8001 of H.R. 5371, the Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extension Act, 2026, Pub. L. 119-37, provisions relating to implementation of Medicare reimbursement cuts under the Statutory Pay-As-You-Go Act of 2010, Pub. L. 111-139; H.R. 6280, the Access to Genetic Counselor Services Act, provisions relating to Medicare coverage of genetic counselor services; H.R. 5582/S. 2355, the Patients Deserve Price Tags Act, provisions relating to lab test price transparency; H.R. 5454/S. 2879, the Medicare Advantage Prompt Pay Act, and H.R. 4559, the Prompt and Fair Pay Act, provisions relating to prompt payment of Medicare Advantage claims; Federal policy relating to access to mandatory code sets for administrative transactions; Federal policy relating to oversight of laboratory-developed tests; and Federal policy relating to supply chain issues affecting pre-clinical biomedical research for drug development.

Healthcare issues related to clinical laboratories; H.R. 5269/S. 2761,the Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act, provisions relating to reform of Medicare reimbursement for clinical laboratory services under Section 216 of the Protecting Access to Medicare Act, Pub. L. 113-93; Federal policy relating to oversight of laboratory-developed tests; Section 71120 of H.R. 1, An Act to provide for reconciliation pursuant to title II of H. Con. Res. 14, provisions relating to modifying cost sharing requirements for certain expansion individuals under the Medicaid program; H.R. 3514/S.1816, the Improving Seniors Timely Access to Care Act, provisions relating to prior authorization of services to Medicare Advantage beneficiaries; S. 2355, the Patients Deserve Price Tags Act, provisions relating to lab test price transparency; H.R. 5444, the Medical Laboratory Personnel Shortage Relief Act, provisions relating to medical laboratory personnel eligibility for the National Health Service Corps and federal grants for lab personnel training; Federal policy relating to implementation of Medicare reimbursement cuts under the Statutory Pay-As-You-Go Act of 2010, Pub. L. 111-139; and Federal policy related to supply chain issues affecting pre-clinical biomedical research for drug development.

Healthcare issues related to clinical laboratories; H.R. 5269/S. 2761,the Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act, provisions relating to reform of Medicare reimbursement for clinical laboratory services under Section 216 of the Protecting Access to Medicare Act, Pub. L. 113-93; Federal policy relating to oversight of laboratory-developed tests; Section 71120 of H.R. 1, An Act to provide for reconciliation pursuant to title II of H. Con. Res. 14, provisions relating to modifying cost sharing requirements for certain expansion individuals under the Medicaid program; H.R. 3514/S.1816, the Improving Seniors Timely Access to Care Act, provisions relating to prior authorization of services to Medicare Advantage beneficiaries; S. 2355, the Patients Deserve Price Tags Act, provisions relating to lab test price transparency; H.R. 5444, the Medical Laboratory Personnel Shortage Relief Act, provisions relating to medical laboratory personnel eligibility for the National Health Service Corps and federal grants for lab personnel training; Federal policy relating to implementation of Medicare reimbursement cuts under the Statutory Pay-As-You-Go Act of 2010, Pub. L. 111-139; and Federal policy related to supply chain issues affecting pre-clinical biomedical research for drug development.

Healthcare issues related to clinical laboratories; H.R. 5269/S. 2761,the Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act, and Section 6209 of the Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extension Act, 2026, Pub. L. 119-37, provisions relating to reform of Medicare reimbursement for clinical laboratory services under Section 216 of the Protecting Access to Medicare Act, Pub. L. 113-93; Section 8001 of H.R. 5371, the Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extension Act, 2026, Pub. L. 119-37, provisions relating to implementation of Medicare reimbursement cuts under the Statutory Pay-As-You-Go Act of 2010, Pub. L. 111-139; H.R. 6280, the Access to Genetic Counselor Services Act, provisions relating to Medicare coverage of genetic counselor services; H.R. 5582/S. 2355, the Patients Deserve Price Tags Act, provisions relating to lab test price transparency; H.R. 5454/S. 2879, the Medicare Advantage Prompt Pay Act, and H.R. 4559, the Prompt and Fair Pay Act, provisions relating to prompt payment of Medicare Advantage claims; Federal policy relating to access to mandatory code sets for administrative transactions; Federal policy relating to oversight of laboratory-developed tests; and Federal policy relating to supply chain issues affecting pre-clinical biomedical research for drug development.

Healthcare issues related to clinical laboratories; H.R. 5269/S. 2761,the Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act, and Section 6209 of the Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extension Act, 2026, Pub. L. 119-37, provisions relating to reform of Medicare reimbursement for clinical laboratory services under Section 216 of the Protecting Access to Medicare Act, Pub. L. 113-93; Section 8001 of H.R. 5371, the Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extension Act, 2026, Pub. L. 119-37, provisions relating to implementation of Medicare reimbursement cuts under the Statutory Pay-As-You-Go Act of 2010, Pub. L. 111-139; H.R. 6280, the Access to Genetic Counselor Services Act, provisions relating to Medicare coverage of genetic counselor services; H.R. 5582/S. 2355, the Patients Deserve Price Tags Act, provisions relating to lab test price transparency; H.R. 5454/S. 2879, the Medicare Advantage Prompt Pay Act, and H.R. 4559, the Prompt and Fair Pay Act, provisions relating to prompt payment of Medicare Advantage claims; Federal policy relating to access to mandatory code sets for administrative transactions; Federal policy relating to oversight of laboratory-developed tests; and Federal policy relating to supply chain issues affecting pre-clinical biomedical research for drug development.

Healthcare issues related to clinical laboratories; H.R. 5269/S. 2761,the Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act, and Section 6209 of the Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extension Act, 2026, Pub. L. 119-37, provisions relating to reform of Medicare reimbursement for clinical laboratory services under Section 216 of the Protecting Access to Medicare Act, Pub. L. 113-93; Section 8001 of H.R. 5371, the Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extension Act, 2026, Pub. L. 119-37, provisions relating to implementation of Medicare reimbursement cuts under the Statutory Pay-As-You-Go Act of 2010, Pub. L. 111-139; H.R. 6280, the Access to Genetic Counselor Services Act, provisions relating to Medicare coverage of genetic counselor services; H.R. 5582/S. 2355, the Patients Deserve Price Tags Act, provisions relating to lab test price transparency; H.R. 5454/S. 2879, the Medicare Advantage Prompt Pay Act, and H.R. 4559, the Prompt and Fair Pay Act, provisions relating to prompt payment of Medicare Advantage claims; Federal policy relating to access to mandatory code sets for administrative transactions; Federal policy relating to oversight of laboratory-developed tests; and Federal policy relating to supply chain issues affecting pre-clinical biomedical research for drug development.

Healthcare issues related to clinical laboratories; H.R. 5269/S. 2761,the Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act, and Section 6209 of the Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extension Act, 2026, Pub. L. 119-37, provisions relating to reform of Medicare reimbursement for clinical laboratory services under Section 216 of the Protecting Access to Medicare Act, Pub. L. 113-93; Section 8001 of H.R. 5371, the Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extension Act, 2026, Pub. L. 119-37, provisions relating to implementation of Medicare reimbursement cuts under the Statutory Pay-As-You-Go Act of 2010, Pub. L. 111-139; H.R. 6280, the Access to Genetic Counselor Services Act, provisions relating to Medicare coverage of genetic counselor services; H.R. 5582/S. 2355, the Patients Deserve Price Tags Act, provisions relating to lab test price transparency; H.R. 5454/S. 2879, the Medicare Advantage Prompt Pay Act, and H.R. 4559, the Prompt and Fair Pay Act, provisions relating to prompt payment of Medicare Advantage claims; Federal policy relating to access to mandatory code sets for administrative transactions; Federal policy relating to oversight of laboratory-developed tests; and Federal policy relating to supply chain issues affecting pre-clinical biomedical research for drug development.

Healthcare issues related to clinical laboratories; H.R. 2377/S. 1000, the Saving Access to Laboratory Services Act (SALSA), Section 301 of H.R. 8261, the Preserving Telehealth, Hospital and Ambulance Access Act, Section 401 of H.R. 7623, the Telehealth Modernization Act, Section 221 of Division B, Title II, Subtitle C of Pub. L. 118-83, 138 Stat. 1524, H.R. 9747, the Continuing Appropriations and Extension Act, 2025, and a draft bill for inflation updates to the Medicare Clinical Laboratory Fee Schedule, provisions relating to reform of Medicare reimbursement for clinical laboratory services under Section 216 of the Protecting Access to Medicare Act, Pub. L. 113-93; H.R. 2369, the Verifying Accurate Leading-edge IVCT Development (VALID) Act, provisions relating to FDA oversight of laboratory-developed tests; H.R. 8818, the American Privacy Rights Act, provisions relating to privacy and security of data; H.R. 8702/S. 4518, the Improving Seniors Timely Access to Care Act, provisions relating to prior authorization of services to Medicare Advantage beneficiaries; Section 106(b) of H.R. 8261, the Preserving Telehealth, Hospital and Ambulance Access Act, and Section 103(b) of H.R. 7623, the Telehealth Modernization Act, provisions relating to Medicare program integrity for clinical diagnostic laboratory test claims; H.R. 1691, the Ensuring Patient Access to Critical Breakthrough Products Act, provisions related to Medicare coverage for breakthrough diagnostics; H.R. 2407, the Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act, provisions relating to reimbursement caps for covered tests; S. 2140, the Patent Eligibility Restoration Act, provisions relating to patent subject matter eligibility; A draft of the Cures 2.0 Act, provisions relating to personalized medicine; A draft of the Correct Coding Improvement Act, provisions related to laboratory procedure coding edits adopted by CMS under the National Correct Coding Initiative (NCCI), the adoption of Proprietary Laboratory Analysis (PLA) codes, and access to mandatory code sets for administrative transactions; Federal policy related to supply chain issues affecting pre-clinical biomedical research for drug development; and Federal policy related to the frequency of U.S. Preventive Services Task Force updates to colorectal cancer screening guidelines.

Healthcare issues related to clinical laboratories; H.R. 2377/S. 1000, the Saving Access to Laboratory Services Act (SALSA), Section 301 of H.R. 8261, the Preserving Telehealth, Hospital and Ambulance Access Act, Section 401 of H.R. 7623, the Telehealth Modernization Act, Section 221 of Division B, Title II, Subtitle C of Pub. L. 118-83, 138 Stat. 1524, H.R. 9747, the Continuing Appropriations and Extension Act, 2025, and a draft bill for inflation updates to the Medicare Clinical Laboratory Fee Schedule, provisions relating to reform of Medicare reimbursement for clinical laboratory services under Section 216 of the Protecting Access to Medicare Act, Pub. L. 113-93; H.R. 2369, the Verifying Accurate Leading-edge IVCT Development (VALID) Act, provisions relating to FDA oversight of laboratory-developed tests; H.R. 8818, the American Privacy Rights Act, provisions relating to privacy and security of data; H.R. 8702/S. 4518, the Improving Seniors Timely Access to Care Act, provisions relating to prior authorization of services to Medicare Advantage beneficiaries; Section 106(b) of H.R. 8261, the Preserving Telehealth, Hospital and Ambulance Access Act, and Section 103(b) of H.R. 7623, the Telehealth Modernization Act, provisions relating to Medicare program integrity for clinical diagnostic laboratory test claims; H.R. 1691, the Ensuring Patient Access to Critical Breakthrough Products Act, provisions related to Medicare coverage for breakthrough diagnostics; H.R. 2407, the Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act, provisions relating to reimbursement caps for covered tests; S. 2140, the Patent Eligibility Restoration Act, provisions relating to patent subject matter eligibility; A draft of the Cures 2.0 Act, provisions relating to personalized medicine; A draft of the Correct Coding Improvement Act, provisions related to laboratory procedure coding edits adopted by CMS under the National Correct Coding Initiative (NCCI), the adoption of Proprietary Laboratory Analysis (PLA) codes, and access to mandatory code sets for administrative transactions; Federal policy related to supply chain issues affecting pre-clinical biomedical research for drug development; and Federal policy related to the frequency of U.S. Preventive Services Task Force updates to colorectal cancer screening guidelines.

Healthcare issues related to clinical laboratories; H.R. 2377/S. 1000, the Saving Access to Laboratory Services Act (SALSA), and a draft bill for inflation updates to the Medicare Clinical Laboratory Fee Schedule, provisions relating to reform of Medicare reimbursement for clinical laboratory services under Section 216 of the Protecting Access to Medicare Act, Pub. L. 113-93; H.R. 2369, the Verifying Accurate Leading-edge IVCT Development (VALID) Act, provisions relating to FDA oversight of laboratory-developed tests, and other Federal policy relating to FDA oversight of laboratory-developed tests; H.R. 8702/S. 4518, the Improving Seniors Timely Access to Care Act, provisions relating to prior authorization of services to Medicare Advantage beneficiaries, and other Federal policy relating to prior authorization of services to Medicare Advantage beneficiaries; H.R. 3876/ S. 2323, the Access to Genetic Counselor Services Act, provisions relating to Medicare coverage of genetic counselor services; A draft of the Correct Coding Improvement Act, provisions related to laboratory procedure coding edits adopted by CMS under the National Correct Coding Initiative (NCCI), the adoption of Proprietary Laboratory Analysis (PLA) codes, and access to mandatory code sets for administrative transactions; Federal policy related to Medicare reimbursement for clinical laboratory tests for Alzheimers disease; Federal policy related to value-based care safe harbors under the federal anti-kickback statute; Federal policy related to supply chain issues affecting pre-clinical biomedical research for drug development; and Federal policy related to the frequency of U.S. Preventive Services Task Force updates to colorectal cancer screening guidelines.

Healthcare issues related to clinical laboratories; H.R. 2377/S. 1000, the Saving Access to Laboratory Services Act (SALSA), Section 301 of H.R. 8261, the Preserving Telehealth, Hospital and Ambulance Access Act, and Section 201 of H.R. 7623, the Telehealth Modernization Act, provisions relating to reform of Medicare reimbursement for clinical laboratory services under Section 216 of the Protecting Access to Medicare Act, Pub. L. 113-93; H.R. 2369, the Verifying Accurate Leading-edge IVCT Development (VALID) Act, provisions relating to FDA oversight of laboratory-developed tests; H.R. 8818, the American Privacy Rights Act, provisions relating to privacy and security of data; H.R. 8702/S. 4518, the Improving Seniors Timely Access to Care Act, provisions relating to prior authorization of services to Medicare Advantage beneficiaries; Section 106(b) of H.R. 8261, the Preserving Telehealth, Hospital and Ambulance Access Act, and Section 103(b) of H.R. 7623, the Telehealth Modernization Act, provisions relating to Medicare program integrity for clinical diagnostic laboratory test claims; A draft of the Correct Coding Improvement Act, provisions related to laboratory procedure coding edits adopted by CMS under the National Correct Coding Initiative (NCCI), the adoption of Proprietary Laboratory Analysis (PLA) codes, and access to mandatory code sets for administrative transactions; Federal policy related to supply chain issues affecting pre-clinical biomedical research for drug development; Federal policy related to the frequency of U.S. Preventive Services Task Force updates to colorectal cancer screening guidelines; and Federal policy related to womens health and digital health solutions.

Healthcare issues related to clinical laboratories; H.R. 2377/S. 1000, the Saving Access to Laboratory Services Act (SALSA), provisions relating to reform of Medicare reimbursement for clinical laboratory services under Section 216 of the Protecting Access to Medicare Act, Pub. L. 113-93; H.R. 2369, the Verifying Accurate Leading-edge IVCT Development (VALID) Act, and the Fiscal Year 2025 Agriculture/FDA Appropriations bill, provisions relating to FDA oversight of laboratory-developed tests; Section 102 of H.R. 5378, the Lower Costs, More Transparency Act, and Section 3 of S. 3548, the Health Care Price Transparency Act 2.0, provisions relating to publication of rates for laboratory services; H.R. 7147/S. 3630, the Medicare Transaction Fraud Prevention Act, provisions relating to a Medicare pilot program using predictive risk algorithms to deny certain claims for clinical laboratory services; S. 3558, a bill to prohibit contracting with certain biotechnology providers; H.R. 7848, the Right Drug Dose Now Act, provisions relating to adoption of pharmacogenomic testing; A draft of the Correct Coding Improvement Act, provisions related to laboratory procedure coding edits adopted by CMS under the National Correct Coding Initiative (NCCI), the adoption of Proprietary Laboratory Analysis (PLA) codes, and access to mandatory code sets for administrative transactions; The Fiscal Year 2025 House and Senate Labor/HHS Appropriations bills, Federal policy related to funding for the CDC to establish lab test result harmonization and pediatric reference intervals; and Federal policy related to supply chain issues affecting pre-clinical biomedical research for drug development.

Healthcare issues related to clinical laboratories; H.R. 2377/S. 1000, the Saving Access to Laboratory Services Act (SALSA), Section 301 of H.R. 8261, the Preserving Telehealth, Hospital and Ambulance Access Act, Section 401 of H.R. 7623, the Telehealth Modernization Act, Section 221 of Division B, Title II, Subtitle C of Pub. L. 118-83, 138 Stat. 1524, H.R. 9747, the Continuing Appropriations and Extension Act, 2025, and a draft bill for inflation updates to the Medicare Clinical Laboratory Fee Schedule, provisions relating to reform of Medicare reimbursement for clinical laboratory services under Section 216 of the Protecting Access to Medicare Act, Pub. L. 113-93; H.R. 2369, the Verifying Accurate Leading-edge IVCT Development (VALID) Act, provisions relating to FDA oversight of laboratory-developed tests; H.R. 8818, the American Privacy Rights Act, provisions relating to privacy and security of data; H.R. 8702/S. 4518, the Improving Seniors Timely Access to Care Act, provisions relating to prior authorization of services to Medicare Advantage beneficiaries; Section 106(b) of H.R. 8261, the Preserving Telehealth, Hospital and Ambulance Access Act, and Section 103(b) of H.R. 7623, the Telehealth Modernization Act, provisions relating to Medicare program integrity for clinical diagnostic laboratory test claims; H.R. 1691, the Ensuring Patient Access to Critical Breakthrough Products Act, provisions related to Medicare coverage for breakthrough diagnostics; H.R. 2407, the Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act, provisions relating to reimbursement caps for covered tests; S. 2140, the Patent Eligibility Restoration Act, provisions relating to patent subject matter eligibility; A draft of the Cures 2.0 Act, provisions relating to personalized medicine; A draft of the Correct Coding Improvement Act, provisions related to laboratory procedure coding edits adopted by CMS under the National Correct Coding Initiative (NCCI), the adoption of Proprietary Laboratory Analysis (PLA) codes, and access to mandatory code sets for administrative transactions; Federal policy related to supply chain issues affecting pre-clinical biomedical research for drug development; and Federal policy related to the frequency of U.S. Preventive Services Task Force updates to colorectal cancer screening guidelines.

Healthcare issues related to clinical laboratories; H.R. 2377/S. 1000, the Saving Access to Laboratory Services Act (SALSA), Section 301 of H.R. 8261, the Preserving Telehealth, Hospital and Ambulance Access Act, and Section 201 of H.R. 7623, the Telehealth Modernization Act, provisions relating to reform of Medicare reimbursement for clinical laboratory services under Section 216 of the Protecting Access to Medicare Act, Pub. L. 113-93; H.R. 2369, the Verifying Accurate Leading-edge IVCT Development (VALID) Act, provisions relating to FDA oversight of laboratory-developed tests; H.R. 8818, the American Privacy Rights Act, provisions relating to privacy and security of data; H.R. 8702/S. 4518, the Improving Seniors Timely Access to Care Act, provisions relating to prior authorization of services to Medicare Advantage beneficiaries; Section 106(b) of H.R. 8261, the Preserving Telehealth, Hospital and Ambulance Access Act, and Section 103(b) of H.R. 7623, the Telehealth Modernization Act, provisions relating to Medicare program integrity for clinical diagnostic laboratory test claims; A draft of the Correct Coding Improvement Act, provisions related to laboratory procedure coding edits adopted by CMS under the National Correct Coding Initiative (NCCI), the adoption of Proprietary Laboratory Analysis (PLA) codes, and access to mandatory code sets for administrative transactions; Federal policy related to supply chain issues affecting pre-clinical biomedical research for drug development; Federal policy related to the frequency of U.S. Preventive Services Task Force updates to colorectal cancer screening guidelines; and Federal policy related to womens health and digital health solutions.

Healthcare issues related to clinical laboratories; H.R. 2377/S. 1000, the Saving Access to Laboratory Services Act (SALSA), and a draft bill for inflation updates to the Medicare Clinical Laboratory Fee Schedule, provisions relating to reform of Medicare reimbursement for clinical laboratory services under Section 216 of the Protecting Access to Medicare Act, Pub. L. 113-93; H.R. 2369, the Verifying Accurate Leading-edge IVCT Development (VALID) Act, provisions relating to FDA oversight of laboratory-developed tests, and other Federal policy relating to FDA oversight of laboratory-developed tests; H.R. 8702/S. 4518, the Improving Seniors Timely Access to Care Act, provisions relating to prior authorization of services to Medicare Advantage beneficiaries, and other Federal policy relating to prior authorization of services to Medicare Advantage beneficiaries; H.R. 3876/ S. 2323, the Access to Genetic Counselor Services Act, provisions relating to Medicare coverage of genetic counselor services; A draft of the Correct Coding Improvement Act, provisions related to laboratory procedure coding edits adopted by CMS under the National Correct Coding Initiative (NCCI), the adoption of Proprietary Laboratory Analysis (PLA) codes, and access to mandatory code sets for administrative transactions; Federal policy related to Medicare reimbursement for clinical laboratory tests for Alzheimers disease; Federal policy related to value-based care safe harbors under the federal anti-kickback statute; Federal policy related to supply chain issues affecting pre-clinical biomedical research for drug development; and Federal policy related to the frequency of U.S. Preventive Services Task Force updates to colorectal cancer screening guidelines.

Healthcare issues related to clinical laboratories; H.R. 2377/S. 1000, the Saving Access to Laboratory Services Act (SALSA), provisions relating to reform of Medicare reimbursement for clinical laboratory services under Section 216 of the Protecting Access to Medicare Act, Pub. L. 113-93; H.R. 2369, the Verifying Accurate Leading-edge IVCT Development (VALID) Act, and the Fiscal Year 2025 Agriculture/FDA Appropriations bill, provisions relating to FDA oversight of laboratory-developed tests; Section 102 of H.R. 5378, the Lower Costs, More Transparency Act, and Section 3 of S. 3548, the Health Care Price Transparency Act 2.0, provisions relating to publication of rates for laboratory services; H.R. 7147/S. 3630, the Medicare Transaction Fraud Prevention Act, provisions relating to a Medicare pilot program using predictive risk algorithms to deny certain claims for clinical laboratory services; S. 3558, a bill to prohibit contracting with certain biotechnology providers; H.R. 7848, the Right Drug Dose Now Act, provisions relating to adoption of pharmacogenomic testing; A draft of the Correct Coding Improvement Act, provisions related to laboratory procedure coding edits adopted by CMS under the National Correct Coding Initiative (NCCI), the adoption of Proprietary Laboratory Analysis (PLA) codes, and access to mandatory code sets for administrative transactions; The Fiscal Year 2025 House and Senate Labor/HHS Appropriations bills, Federal policy related to funding for the CDC to establish lab test result harmonization and pediatric reference intervals; and Federal policy related to supply chain issues affecting pre-clinical biomedical research for drug development.

Healthcare issues related to clinical laboratories; H.R. 2377/S. 1000, the Saving Access to Laboratory Services Act (SALSA), Section 301 of H.R. 8261, the Preserving Telehealth, Hospital and Ambulance Access Act, Section 401 of H.R. 7623, the Telehealth Modernization Act, Section 221 of Division B, Title II, Subtitle C of Pub. L. 118-83, 138 Stat. 1524, H.R. 9747, the Continuing Appropriations and Extension Act, 2025, and a draft bill for inflation updates to the Medicare Clinical Laboratory Fee Schedule, provisions relating to reform of Medicare reimbursement for clinical laboratory services under Section 216 of the Protecting Access to Medicare Act, Pub. L. 113-93; H.R. 2369, the Verifying Accurate Leading-edge IVCT Development (VALID) Act, provisions relating to FDA oversight of laboratory-developed tests; H.R. 8818, the American Privacy Rights Act, provisions relating to privacy and security of data; H.R. 8702/S. 4518, the Improving Seniors Timely Access to Care Act, provisions relating to prior authorization of services to Medicare Advantage beneficiaries; Section 106(b) of H.R. 8261, the Preserving Telehealth, Hospital and Ambulance Access Act, and Section 103(b) of H.R. 7623, the Telehealth Modernization Act, provisions relating to Medicare program integrity for clinical diagnostic laboratory test claims; H.R. 1691, the Ensuring Patient Access to Critical Breakthrough Products Act, provisions related to Medicare coverage for breakthrough diagnostics; H.R. 2407, the Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act, provisions relating to reimbursement caps for covered tests; S. 2140, the Patent Eligibility Restoration Act, provisions relating to patent subject matter eligibility; A draft of the Cures 2.0 Act, provisions relating to personalized medicine; A draft of the Correct Coding Improvement Act, provisions related to laboratory procedure coding edits adopted by CMS under the National Correct Coding Initiative (NCCI), the adoption of Proprietary Laboratory Analysis (PLA) codes, and access to mandatory code sets for administrative transactions; Federal policy related to supply chain issues affecting pre-clinical biomedical research for drug development; and Federal policy related to the frequency of U.S. Preventive Services Task Force updates to colorectal cancer screening guidelines.

Healthcare issues related to clinical laboratories; H.R. 2377/S. 1000, the Saving Access to Laboratory Services Act (SALSA), and a draft bill for inflation updates to the Medicare Clinical Laboratory Fee Schedule, provisions relating to reform of Medicare reimbursement for clinical laboratory services under Section 216 of the Protecting Access to Medicare Act, Pub. L. 113-93; H.R. 2369, the Verifying Accurate Leading-edge IVCT Development (VALID) Act, provisions relating to FDA oversight of laboratory-developed tests, and other Federal policy relating to FDA oversight of laboratory-developed tests; H.R. 8702/S. 4518, the Improving Seniors Timely Access to Care Act, provisions relating to prior authorization of services to Medicare Advantage beneficiaries, and other Federal policy relating to prior authorization of services to Medicare Advantage beneficiaries; H.R. 3876/ S. 2323, the Access to Genetic Counselor Services Act, provisions relating to Medicare coverage of genetic counselor services; A draft of the Correct Coding Improvement Act, provisions related to laboratory procedure coding edits adopted by CMS under the National Correct Coding Initiative (NCCI), the adoption of Proprietary Laboratory Analysis (PLA) codes, and access to mandatory code sets for administrative transactions; Federal policy related to Medicare reimbursement for clinical laboratory tests for Alzheimers disease; Federal policy related to value-based care safe harbors under the federal anti-kickback statute; Federal policy related to supply chain issues affecting pre-clinical biomedical research for drug development; and Federal policy related to the frequency of U.S. Preventive Services Task Force updates to colorectal cancer screening guidelines.

Healthcare issues related to clinical laboratories; H.R. 2377/S. 1000, the Saving Access to Laboratory Services Act (SALSA), provisions relating to reform of Medicare reimbursement for clinical laboratory services under Section 216 of the Protecting Access to Medicare Act, Pub. L. 113-93; H.R. 2369, the Verifying Accurate Leading-edge IVCT Development (VALID) Act, and the Fiscal Year 2025 Agriculture/FDA Appropriations bill, provisions relating to FDA oversight of laboratory-developed tests; Section 102 of H.R. 5378, the Lower Costs, More Transparency Act, and Section 3 of S. 3548, the Health Care Price Transparency Act 2.0, provisions relating to publication of rates for laboratory services; H.R. 7147/S. 3630, the Medicare Transaction Fraud Prevention Act, provisions relating to a Medicare pilot program using predictive risk algorithms to deny certain claims for clinical laboratory services; S. 3558, a bill to prohibit contracting with certain biotechnology providers; H.R. 7848, the Right Drug Dose Now Act, provisions relating to adoption of pharmacogenomic testing; A draft of the Correct Coding Improvement Act, provisions related to laboratory procedure coding edits adopted by CMS under the National Correct Coding Initiative (NCCI), the adoption of Proprietary Laboratory Analysis (PLA) codes, and access to mandatory code sets for administrative transactions; The Fiscal Year 2025 House and Senate Labor/HHS Appropriations bills, Federal policy related to funding for the CDC to establish lab test result harmonization and pediatric reference intervals; and Federal policy related to supply chain issues affecting pre-clinical biomedical research for drug development.

Section 201 of H.R. 7024, the Tax Relief for American Families and Workers Act, provisions relating to immediate deductibility of research and development expenses under Internal Revenue Code Section 174.

Section 201 of H.R. 7024, the Tax Relief for American Families and Workers Act, provisions relating to immediate deductibility of research and development expenses under Internal Revenue Code Section 174.

Healthcare issues related to clinical laboratories; H.R. 2377/S. 1000, the Saving Access to Laboratory Services Act (SALSA), provisions relating to reform of Medicare reimbursement for clinical laboratory services under Section 216 of the Protecting Access to Medicare Act, Pub. L. 113-93; H.R. 2369, the Verifying Accurate Leading-edge IVCT Development (VALID) Act, and the Fiscal Year 2025 Agriculture/FDA Appropriations bill, provisions relating to FDA oversight of laboratory-developed tests; Section 102 of H.R. 5378, the Lower Costs, More Transparency Act, and Section 3 of S. 3548, the Health Care Price Transparency Act 2.0, provisions relating to publication of rates for laboratory services; H.R. 7147/S. 3630, the Medicare Transaction Fraud Prevention Act, provisions relating to a Medicare pilot program using predictive risk algorithms to deny certain claims for clinical laboratory services; S. 3558, a bill to prohibit contracting with certain biotechnology providers; H.R. 7848, the Right Drug Dose Now Act, provisions relating to adoption of pharmacogenomic testing; A draft of the Correct Coding Improvement Act, provisions related to laboratory procedure coding edits adopted by CMS under the National Correct Coding Initiative (NCCI), the adoption of Proprietary Laboratory Analysis (PLA) codes, and access to mandatory code sets for administrative transactions; The Fiscal Year 2025 House and Senate Labor/HHS Appropriations bills, Federal policy related to funding for the CDC to establish lab test result harmonization and pediatric reference intervals; and Federal policy related to supply chain issues affecting pre-clinical biomedical research for drug development.

Healthcare issues related to clinical laboratories; H.R. 2377/S. 1000, the Saving Access to Laboratory Services Act (SALSA), Section 301 of H.R. 8261, the Preserving Telehealth, Hospital and Ambulance Access Act, and Section 201 of H.R. 7623, the Telehealth Modernization Act, provisions relating to reform of Medicare reimbursement for clinical laboratory services under Section 216 of the Protecting Access to Medicare Act, Pub. L. 113-93; H.R. 2369, the Verifying Accurate Leading-edge IVCT Development (VALID) Act, provisions relating to FDA oversight of laboratory-developed tests; H.R. 8818, the American Privacy Rights Act, provisions relating to privacy and security of data; H.R. 8702/S. 4518, the Improving Seniors Timely Access to Care Act, provisions relating to prior authorization of services to Medicare Advantage beneficiaries; Section 106(b) of H.R. 8261, the Preserving Telehealth, Hospital and Ambulance Access Act, and Section 103(b) of H.R. 7623, the Telehealth Modernization Act, provisions relating to Medicare program integrity for clinical diagnostic laboratory test claims; A draft of the Correct Coding Improvement Act, provisions related to laboratory procedure coding edits adopted by CMS under the National Correct Coding Initiative (NCCI), the adoption of Proprietary Laboratory Analysis (PLA) codes, and access to mandatory code sets for administrative transactions; Federal policy related to supply chain issues affecting pre-clinical biomedical research for drug development; Federal policy related to the frequency of U.S. Preventive Services Task Force updates to colorectal cancer screening guidelines; and Federal policy related to womens health and digital health solutions.

Healthcare issues related to clinical laboratories; H.R. 2377/S. 1000, the Saving Access to Laboratory Services Act (SALSA), Section 301 of H.R. 8261, the Preserving Telehealth, Hospital and Ambulance Access Act, Section 401 of H.R. 7623, the Telehealth Modernization Act, Section 221 of Division B, Title II, Subtitle C of Pub. L. 118-83, 138 Stat. 1524, H.R. 9747, the Continuing Appropriations and Extension Act, 2025, and a draft bill for inflation updates to the Medicare Clinical Laboratory Fee Schedule, provisions relating to reform of Medicare reimbursement for clinical laboratory services under Section 216 of the Protecting Access to Medicare Act, Pub. L. 113-93; H.R. 2369, the Verifying Accurate Leading-edge IVCT Development (VALID) Act, provisions relating to FDA oversight of laboratory-developed tests; H.R. 8818, the American Privacy Rights Act, provisions relating to privacy and security of data; H.R. 8702/S. 4518, the Improving Seniors Timely Access to Care Act, provisions relating to prior authorization of services to Medicare Advantage beneficiaries; Section 106(b) of H.R. 8261, the Preserving Telehealth, Hospital and Ambulance Access Act, and Section 103(b) of H.R. 7623, the Telehealth Modernization Act, provisions relating to Medicare program integrity for clinical diagnostic laboratory test claims; H.R. 1691, the Ensuring Patient Access to Critical Breakthrough Products Act, provisions related to Medicare coverage for breakthrough diagnostics; H.R. 2407, the Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act, provisions relating to reimbursement caps for covered tests; S. 2140, the Patent Eligibility Restoration Act, provisions relating to patent subject matter eligibility; A draft of the Cures 2.0 Act, provisions relating to personalized medicine; A draft of the Correct Coding Improvement Act, provisions related to laboratory procedure coding edits adopted by CMS under the National Correct Coding Initiative (NCCI), the adoption of Proprietary Laboratory Analysis (PLA) codes, and access to mandatory code sets for administrative transactions; Federal policy related to supply chain issues affecting pre-clinical biomedical research for drug development; and Federal policy related to the frequency of U.S. Preventive Services Task Force updates to colorectal cancer screening guidelines.

Healthcare issues related to clinical laboratories; H.R. 2377/S. 1000, the Saving Access to Laboratory Services Act (SALSA), provisions relating to reform of Medicare reimbursement for clinical laboratory services under Section 216 of the Protecting Access to Medicare Act, Pub. L. 113-93; H.R. 2369, the Verifying Accurate Leading-edge IVCT Development (VALID) Act, and the Fiscal Year 2025 Agriculture/FDA Appropriations bill, provisions relating to FDA oversight of laboratory-developed tests; Section 102 of H.R. 5378, the Lower Costs, More Transparency Act, and Section 3 of S. 3548, the Health Care Price Transparency Act 2.0, provisions relating to publication of rates for laboratory services; H.R. 7147/S. 3630, the Medicare Transaction Fraud Prevention Act, provisions relating to a Medicare pilot program using predictive risk algorithms to deny certain claims for clinical laboratory services; S. 3558, a bill to prohibit contracting with certain biotechnology providers; H.R. 7848, the Right Drug Dose Now Act, provisions relating to adoption of pharmacogenomic testing; A draft of the Correct Coding Improvement Act, provisions related to laboratory procedure coding edits adopted by CMS under the National Correct Coding Initiative (NCCI), the adoption of Proprietary Laboratory Analysis (PLA) codes, and access to mandatory code sets for administrative transactions; The Fiscal Year 2025 House and Senate Labor/HHS Appropriations bills, Federal policy related to funding for the CDC to establish lab test result harmonization and pediatric reference intervals; and Federal policy related to supply chain issues affecting pre-clinical biomedical research for drug development.

Healthcare issues related to clinical laboratories; H.R. 2377/S. 1000, the Saving Access to Laboratory Services Act (SALSA), Section 301 of H.R. 8261, the Preserving Telehealth, Hospital and Ambulance Access Act, and Section 201 of H.R. 7623, the Telehealth Modernization Act, provisions relating to reform of Medicare reimbursement for clinical laboratory services under Section 216 of the Protecting Access to Medicare Act, Pub. L. 113-93; H.R. 2369, the Verifying Accurate Leading-edge IVCT Development (VALID) Act, provisions relating to FDA oversight of laboratory-developed tests; H.R. 8818, the American Privacy Rights Act, provisions relating to privacy and security of data; H.R. 8702/S. 4518, the Improving Seniors Timely Access to Care Act, provisions relating to prior authorization of services to Medicare Advantage beneficiaries; Section 106(b) of H.R. 8261, the Preserving Telehealth, Hospital and Ambulance Access Act, and Section 103(b) of H.R. 7623, the Telehealth Modernization Act, provisions relating to Medicare program integrity for clinical diagnostic laboratory test claims; A draft of the Correct Coding Improvement Act, provisions related to laboratory procedure coding edits adopted by CMS under the National Correct Coding Initiative (NCCI), the adoption of Proprietary Laboratory Analysis (PLA) codes, and access to mandatory code sets for administrative transactions; Federal policy related to supply chain issues affecting pre-clinical biomedical research for drug development; Federal policy related to the frequency of U.S. Preventive Services Task Force updates to colorectal cancer screening guidelines; and Federal policy related to womens health and digital health solutions.

Healthcare issues related to clinical laboratories; H.R. 2377/S. 1000, the Saving Access to Laboratory Services Act (SALSA), Section 301 of H.R. 8261, the Preserving Telehealth, Hospital and Ambulance Access Act, Section 401 of H.R. 7623, the Telehealth Modernization Act, Section 221 of Division B, Title II, Subtitle C of Pub. L. 118-83, 138 Stat. 1524, H.R. 9747, the Continuing Appropriations and Extension Act, 2025, and a draft bill for inflation updates to the Medicare Clinical Laboratory Fee Schedule, provisions relating to reform of Medicare reimbursement for clinical laboratory services under Section 216 of the Protecting Access to Medicare Act, Pub. L. 113-93; H.R. 2369, the Verifying Accurate Leading-edge IVCT Development (VALID) Act, provisions relating to FDA oversight of laboratory-developed tests; H.R. 8818, the American Privacy Rights Act, provisions relating to privacy and security of data; H.R. 8702/S. 4518, the Improving Seniors Timely Access to Care Act, provisions relating to prior authorization of services to Medicare Advantage beneficiaries; Section 106(b) of H.R. 8261, the Preserving Telehealth, Hospital and Ambulance Access Act, and Section 103(b) of H.R. 7623, the Telehealth Modernization Act, provisions relating to Medicare program integrity for clinical diagnostic laboratory test claims; H.R. 1691, the Ensuring Patient Access to Critical Breakthrough Products Act, provisions related to Medicare coverage for breakthrough diagnostics; H.R. 2407, the Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act, provisions relating to reimbursement caps for covered tests; S. 2140, the Patent Eligibility Restoration Act, provisions relating to patent subject matter eligibility; A draft of the Cures 2.0 Act, provisions relating to personalized medicine; A draft of the Correct Coding Improvement Act, provisions related to laboratory procedure coding edits adopted by CMS under the National Correct Coding Initiative (NCCI), the adoption of Proprietary Laboratory Analysis (PLA) codes, and access to mandatory code sets for administrative transactions; Federal policy related to supply chain issues affecting pre-clinical biomedical research for drug development; and Federal policy related to the frequency of U.S. Preventive Services Task Force updates to colorectal cancer screening guidelines.

Healthcare issues related to clinical laboratories; H.R. 2377/S. 1000, the Saving Access to Laboratory Services Act (SALSA), Section 301 of H.R. 8261, the Preserving Telehealth, Hospital and Ambulance Access Act, and Section 201 of H.R. 7623, the Telehealth Modernization Act, provisions relating to reform of Medicare reimbursement for clinical laboratory services under Section 216 of the Protecting Access to Medicare Act, Pub. L. 113-93; H.R. 2369, the Verifying Accurate Leading-edge IVCT Development (VALID) Act, provisions relating to FDA oversight of laboratory-developed tests; H.R. 8818, the American Privacy Rights Act, provisions relating to privacy and security of data; H.R. 8702/S. 4518, the Improving Seniors Timely Access to Care Act, provisions relating to prior authorization of services to Medicare Advantage beneficiaries; Section 106(b) of H.R. 8261, the Preserving Telehealth, Hospital and Ambulance Access Act, and Section 103(b) of H.R. 7623, the Telehealth Modernization Act, provisions relating to Medicare program integrity for clinical diagnostic laboratory test claims; A draft of the Correct Coding Improvement Act, provisions related to laboratory procedure coding edits adopted by CMS under the National Correct Coding Initiative (NCCI), the adoption of Proprietary Laboratory Analysis (PLA) codes, and access to mandatory code sets for administrative transactions; Federal policy related to supply chain issues affecting pre-clinical biomedical research for drug development; Federal policy related to the frequency of U.S. Preventive Services Task Force updates to colorectal cancer screening guidelines; and Federal policy related to womens health and digital health solutions.